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THE ROLE OF CURCUMIN IN HUMAN DENDNRITIC CELL
MATURATION AND FUNCTION
Shawna A. Shirley, M.S.
ABSTRACT

Curcumin is the yellow pigment found in the Indian spice curry. It has antiinflammatory, ant-oxidant, anti-cancer, anti-viral, anti-bacterial and wound
healing properties. It is widely used in industry for its flavor as a spice and as a
coloring agent because of its brilliant yellow color. It is also used as a dye for
textiles and as an additive to cosmetics. Dendritic cells (DCs) are the sentinels of
the immune system and functions as the bridge between the innate and adaptive
immune response. The effect of curcumin on DCs is poorly understood. A study
shows curcumin prevents the immuno-stimulatory function of bone marrowderived murine DCs, but no study examines the effects on human DCs. This
study investigates the effects of curcumin on immature human DC maturation
and function in response to immune stimulants lipopolysaccharide (LPS) and
polyinosinic-polycytidylic acid (poly I:C).
Human CD14+ monocytes isolated from the peripheral blood of donors
are cultured with GM-CSF and IL-4 supplemented media to generate immature
DCs. The cultures are treated with curcumin, stimulated with the above
xii

mentioned stimulants then functional assays performed. These assays include
homotypic cluster formation, surface marker expression, cytokine production,
chemotaxis, endocytosis, DC-induced allogeneic CD4+ T cell proliferation after
mixed lymphocyte reaction, gene expression analysis and immuno-fluorescence
labeling and imaging. Curcumin-induced changes in gene expression indicate the
actin cytoskeleton signaling pathway is a target. Immuno-fluorescence labeling
and imaging of f-actin was carried out.
Curcumin reduces DC maturation in response to the stimulants used in
the study. Expression of surface markers, cytokines and chemokines is reduced
as well as DC-induced stimulation of allogeneic CD4+ cells after MLR. Curcumin
prevents chemotaxis without affecting chemokine receptor expression and
significantly reduces endocytosis in non-stimulated cells. Curcumin-treated DCs
do not induce a Th1 or Th2 population in allogeneic MLR but induces a
CD25+Foxp3+ regulatory cell population. Immuno-fluorescence imaging shows
curcumin causes the cell to become more rounded. These data imply that
curcumin inhibits f-actin polymerization and thereby prevents DC maturation and
function in response to stimulation. This outlines a novel role for curcumin as an
immune suppressant and shows its therapeutic potential as an anti-inflammatory
agent.
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INTRODUCTION

Turmeric is a bright yellow spice derived from the root of the perennial
Curcumin longa, a member of the ginger family. Curcumin, also called
diferuloylmethane, is the most biologically active compound turmeric and belongs
to a family of compounds called curcuminoids which usually comprises about 3%
of turmeric powder. The spice is widely used for its culinary flavor as it gives
curry its characteristic taste. Its use also extends to medicine. For centuries it has
been used in Asian cultures in Ayurvedic systems of medicine most likely
because of its properties as an antiseptic, analgesic, appetite suppressant, antiinflammatory agent, antioxidant, anti-malarial and insect repellant (3, 49). In
industry it is commonly used as a food preservative, a yellow dye or coloring for
food and textiles and as an ingredient in pharmaceuticals and cosmetics.
Research shows curcumin has anti-inflammatory, antioxidant, antiparasitic, anti-viral and anti-cancer properties (12, 74, 88, 91). It targets
transcription factors, cytokines, cell adhesion molecules, surface receptors,
growth factors and kinases, among other molecules (9, 72, 78, 152), and directly
binds to a variety of surface and intracellular proteins causing direct cellular
pathway inhibition or activation of secondary cellular responses (3, 48).
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A Natural History of Curcumin
Curcumin was first isolated from turmeric in 1815 and its 1910 its chemical
structure was determined as C21H20O6 by Vogel and Pellatier (145). The history
of curcumin however, dates back over 5000 years to the time of Ayurveda.
Ayurveda, or the science of good life, is an ancient system of healthcare
practiced in India. In this system of medicine curcumin was used for wound
healing, blood cleansing and to cure stomach illnesses. Also known as Haldi,
curcumin has been used for centuries without known side effects as a food
preservative or additive for coloring and flavor. It can be ingested to treat a host
of internal ailments or mixed into a paste and applied topically to treat wounds,
bruises, boils pains, sprains, swellings and other disorders of the skin (61).
Curcumin is a valuable export crop and is widely cultivated by Asian countries. In
addition to its culinary and medicinal uses, it is also commonly used in industry
as a food preservative, a yellow dye or coloring for food and textiles and as an
ingredient in pharmaceuticals and cosmetics (128). In Hindu religious
ceremonies it is mixed with sandalwood powder and applied to the forehead (61).
The earliest entry about curcumin in PubMed is from 1949, a study
published in Nature explored the antibacterial action of curcumin (115). To date
there are 2438 articles in PubMed related to curcumin.
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Curcumin Classification and Structure
Taxonomically, turmeric belongs to Class Liliopsida; Subclass
Commelinids; Order Zingiberales; Family Zingiberaceae; Genus Curcuma;
Species Curcuma longa (ref). It is a hydrophobic, polyphenolic compound that is
soluble in ethanol, dimethyl sulfoxide, acetone, chloroform and oils. Curcumin
exists in both keto and enol forms, but the keto form is more energetically stable
(Figure 1). Its absorption maxima is around 420 nm and therefore it fluoresces at
the wavelength of FITC. Most commercially available preparations of curcumin
contain other compounds such as its analogs demethoxycurcumin and
bisdemethoxycurcumin (3). Though curcumin is thought to be the most potent of
the three, it is unclear whether the other analogs have similar activity (4, 127). It
is suggested that the combination of all three is more potent than each
individually (58).

Molecular Targets and Receptors of Curcumin
The lipophilic property of curcumin allows it to rapidly permeate cell
membranes and enter the cytoplasm (62). There are proteins to which curcumin
binds and initiates secondary cellular responses. These include, among others,
5-LOX, serum albumin, iron, IKK, PKC, PKA, GST and autophosphorylationactivated protein kinase (3). Due to its size and chemical composition, it is
possible that curcumin enters cells by passive diffusion though the lipid bi-layer.
Its anti-inflammatory properties are ascribed to its ability to inhibit transcription
factors such as NFκB, AP-1 and STATs, its ability to reduce COX-2 and 5-LOX
3

expression and its ability to reduce the expression of surface adhesion
molecules. Its role as a potent antioxidant may also contribute to its antiinflammatory actions (3, 15, 118, 143). Antioxidants are compounds that delay or
arrest disease progression. Curcumin functions as an antioxidant by inducing the
expression of reactive oxygen species (ROS) and binding iron (39, 155). The
structure of curcumin is rich in hydroxyl and methoxyl groups. There is some
debate over whether it is the methylenic group at center or the phenol groups
that contribute the hydrogen atom that confer its antioxidant property (16, 65,
107).

Keto

Enol
Figure1. Structure of curcumin (diferuloylmethane) in both keto and enol forms (reprinted from
Wikipedia)
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Anti-inflammatory Activity of Curcumin
The anti-inflammatory property of curcumin is thought to be responsible
for many of the activities associated with curcumin. It has been suggested that
this property is directly related to the structure of the molecule, though there is
debate over which portion is responsible; the diene bonds in the center or the
phenol groups at either end (12, 27, 28, 70). Another notable property of
curcumin related to its role as an anti-inflammatory agent is its antitumor activity.
Curcumin can alter multiple signaling pathways by interacting with a number of
molecular targets (3, 10) and function as a chemopreventative agent. It
suppresses multiple forms of cancer including cancers of the breast, colon, liver,
oral cavity and prostate.
Curcumin inhibits proliferation of an array of tumor cell types in vitro (2)
and prevents metastasis in an in vitro model of mouse melanoma (93). It
interferes with angiogenesis by inhibiting fibroblast growth factor (FGF)-induced
neovascularization and inhibits vascular endothelial growth factor (VEGF)
expression (13, 52, 94). Adhesion molecule expression is important for tumor
metastasis. Curcumin may mediate its anti-tumor effects partially by reducing
adhesion molecule expression (19, 138). Curcumin also modulates matrix
metalloproteinases (MMPs) that regulate endothelial cell migration and
attachment (82). Curcumin affects multiple signaling pathways including key
pathways regulated by transcription factors NF-κB, AP-1, Akt and Nrf2 (2, 54).
These pathways control the production of cytokines and other inflammatory
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mediators, cell proliferation and apoptosis. Modulation of these pathways by
curcumin has a direct impact on tumor progression and survival.

Pharmacology and Pharmacokinetics of Curcumin
Turmeric has been classified by The Food and Drug Administration among
substances Generally Recognized as Safe (GRAS). It has been shown to be safe
at high doses in humans, rats, mice , monkeys and guinea pigs (26, 116, 117). It
has also been tested for mutagenicity using the Ames test and has been shown
to be nonmutagenic (97). Curcumin has been safely used as a dietary spice for
centuries without adverse effects. An estimated 200mg of curcumin is ingested
daily by Indian adults (29, 49). The only adverse effects noted in the literature are
rare cases of allergic contact dermatitis (46, 53). No adverse drug interactions
have been reported (49).
Turmeric contains turmerin, essential oils (turmerones, altanones and
zingiberene), curcumin, flavanoids, resins, proteins and sugars. Curcumin is the
most biologically active compound found in turmeric and comprises about 2 to 8
percent of turmeric preparations (137). It is estimated that about 40-85% of
curcumin remains unaltered after ingestion in the gastrointestinal tract where it is
absorbed by the intestinal mucosa (109, 146). The oral toxicity of curcumin is
low. Human clinical trials indicate no toxicity at doses as high as 12g/day (11).
The oral bioavailability of curcumin is also very low due to its rapid metabolism in
the intestinal mucosa and liver. Humans given about 3g/day had undetectable or
very low serum levels (119, 122). One study reports a patient with a serum
6

concentration of 58ng/ml two hours and 51ng/ml four hours after receiving 12g of
curcumin. Another patient had serum levels of 51ng/ml four hours after receiving
a 10g dosage (79).
The degradation kinetics and stability of curcumin in physiological
conditions vary. Degradation is pH dependent. At neutral or basic pH, the
degradation is rapid, while more acidic conditions promote slower degradation. In
0.1M phosphate buffer and serum free media curcumin is degraded by about
90% over 30 minutes. In culture medium containing 10% fetal calf serum and in
human blood only 20% of curcumin is degraded after 1 hour. After 8 hours 50%
still remained (148). Byproducts of curcumin metabolism differ based on the
route of delivery; when given orally, curcumin sulfonate and curcumin
glucuronide are produced but when given intraperitoneally or systemically
tetrahydrocurcumin is produced. It is unclear whether these metabolites are
biologically active, though tetrahydrocurcumin is active in some systems (103,
104, 130) but not others (60, 98).
The rapid metabolism and poor bioavailability of curcumin impedes its use
as an orally delivered drug. A study by Shoba et al. showed that combining
piperine, a known inhibitor of hepatic and intestinal glucuronidation, with
curcumin significantly increases its oral bioavailability in humans and rats (122).
A more recent approach is to use polymeric nanoparticle-encapsulated curcumin
or “nanocurcumin” as a novel formulation to deliver curcumin (20).
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Curcumin in the Clinic
The ability of curcumin to modulate multiple molecular targets, coupled
with its pharmacological safety and low cost make it attractive for clinical
research. There are currently about twenty-five clinical trials examining the
therapeutic potential and efficacy of curcumin (www.clinicaltrials.gov). These are
outlined in a few review articles (10, 45, 54). Initial results are positive in some
subsets of patients when curcumin is used to treat cancer and inflammatory
conditions including idiopathic inflammatory orbital pseudo tumors, postoperative inflammation, external cancerous lesions and pancreatic cancer (33,
75-77, 112). Other disease targets being considered include psoriasis and
Alzheimer’s disease.

Dendritic Cell Biology
Dendritic cells are the sentinels of the immune system and regulate the
immune response. They are widely distributed throughout the body and exist in
two functionally distinct states; immature and mature. Immature or resting
dendritic cells reside in peripheral organs where they monitor the surrounding
tissue for invading microorganisms. They alert the immune system to the
presence of pathogens by engulfing them, processing the foreign proteins and
presenting the peptide fragments on their surface. After DCs are activated, they
mature and migrate to the lymphoid tissue where they prime naïve T
lymphocytes and stimulate a specific or adaptive response (50, 92, 129).
Immature DCs express relatively low levels of co-stimulatory and antigen
8

presenting molecules but have a high endocytic capacity while mature DCs
express higher levels of these markers and a reduced endocytic capacity.
Maturation of dendritic cells involves changes in gene expression, activation of
signaling pathways and substantial cytoplasmic reorganization. mDCs extend
long dendritic processes that increase the cell surface area that enhances the
opportunity for T cell interaction (92). The changes that occur in the DC during
the maturation process are regulated by actin assembly and disassembly
mediated by the Rho family of GTPases which include Rho, Rac and Cdc42 (24,
43, 100, 124, 133, 151).
Maturation of DCs is a key step in the initiation of immunity. Decreased
endocytosis, increased migration and the increased ability to stimulate
proliferation and differentiation of T cells are characteristics of mature DCs.
Another characteristic feature of mature DCs is their ability to form cellular
aggregates or homotypic clusters (37). Cluster formation has been observed in
vivo with cutaneous Langerhan’s cells as well as in vitro (31, 84, 150). It has
been shown that cluster formation is not an accidental encounter between
migrating cells, but rather has a physiological function to enhance maturation.
Clustering results in increased CD86, CD80 and CD54 marker expression, and a
modest increase in the ability to stimulate T cells in a syngeneic MLR (31). The
authors also suggest clustering facilitates antigen transfer between maturing
DCs.
Immature DCs are quite different from mature cells. They can take up
particles, antigen and microorganisms by phagocytosis and they express
9

receptors that mediate endocytosis (64, 132). Once iDCs have captured antigens
or particles, their ability to capture more quickly decreases. The antigens enter
the endocytic pathway where they are processed and presented on the surface
of the cell in the context of MHCII molecules (25, 106).
Primed DCs will migrate to secondary lymphoid organs and present the
antigen-peptide-MHC complexes to naïve CD4+ T cells and cytotoxic CD8+ T
cells which induce differentiate into memory and effector cells. The mixed
lymphocyte reaction (MLR) can be used as an in vitro model of DC-TC
interaction. DCs will stimulate proliferation of the T cells in co-culture and drive a
specific phenotype based on the cytokine environment and the type and
activation state of the DCs (32, 135). The ratio of DCs to TCs will influence the
phenotype of T cells produced. A low ratio induces a Th2 population, while a high
ratio induced mixed Th1/Th2 cell development (135).
DC migration is regulated by chemokine and chemokine receptor
interactions with the aid of accessory proteins (38). The chemokine receptor
CCR7 plays and important role in DC migration. Mature DCs upregulate CCR7
expression to improve their responsiveness to its ligands CCL21 and CCL19.
CCL21 is important in guiding the maturing DCs to the lymphatic vessels and
CCL19 guides cells to the T-cell zones of the lymphoid tissues (30, 35, 36, 51,
85).
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The Actin Cytoskeleton
The actin cytoskeleton provides the scaffolding of the cell that helps to
maintain its shape. Most dendritic cell functions are controlled by cytoskeletal
rearrangement. Individual units of actin, globular actin (g-actin), assemble in long
polymer filaments to from filamentous actin (f-actin). Two parallel strands of factin twist around each other to form the microfilaments of the cytoskeleton.
Antigen capture, antigen presentation, cell adherence and cell migration is
regulated by the Rho family of GTPases which regulate actin cytoskeleton
organization (14, 43, 95, 100). The engagement of T cells by DCs is also
dependent on cytoskeletal rearrangement for formation of the immunological
synapse (5, 6). The Rho family of GTPases belongs to the larger Ras
superfamily of GTP-binding proteins. The Rho subfamily consist of more than
twenty distinct proteins including RhoA, RhoB, RhoC, RhoD, RhoE, Rac1, Rac2
and Cdc42 (124). The Rho GTPases function by cycling between the active
GTP-bound state and the inactive GDP-bound state (22). Regulation of
endocytosis is in part due to the levels of activated Cdc42 (43). Cdc42, Rac and
Rho are involved in antigen presentation in DCs as well as motility, adhesion and
chemotaxis (7, 8, 124). Regulation of the DC cytoskeleton is largely
developmentally regulated (24).
The Wiskott-Aldrich syndrome protein (WASP) is the specific effector of
Cdc42 (141). It is expressed mainly in hematopoietic cells and its functions as a
signal transducer to the actin cytoskeleton (140). WASP is also important in
filapodia formation, adhesion marker expression and DC chemotaxis (7, 8, 140).
11

WASP binds the actin related protein (Arp) 2/3 complex. Together they regulate
the actin cytoskeleton by nucleating the actin filament assembly to create a
branching network at podosomes that govern the directional movement of DCs
(21, 96, 154).
Nexilin is an f-actin binding protein localized at the cell-matrix adherens
junction that was first described in 1998 in rat brain and fibroblasts by Ohtsuka et
al (102). Nelin (nexilin-like protein) is the human homolog of nexilin found
primarily in the heart, skeletal muscle, artery and vein. Based on structural
analysis, it can regulate the formation of stress fibers and focal adhesions (156).
In HeLa cells it stimulates migration and adhesion and so mediates cell motility
(147). The role nelin plays in dendritic cell function is unknown.

Curcumin and the Actin Cytoskeleton
Little is know about how curcumin affects cytoskeleton of the cell. A few
studies have examined the effects of curcumin on the actin cytoskeleton in
neurons, hepatic cells and cancer cells but none have outlined these effects in
dendritic cells. In an in vitro study using prostate cancer cells, curcumin shows
profound effects on actin-based motility and microfilament organization (56). The
actin inhibitor chytochalasin B was used in this study as a control. Curcumin
shows similar inhibitory effects. Cyclin-dependent kinase 1A (p21) functions as a
regulator of cell cycle progression at the S phase. p21-activated kinases (PAKs)
also participate in the regulation actin filaments along with the Rho GTPases.
Curcumin suppresses PAK translocation in aged Tg2576 transgenic mice with
12

Alzheimer amyloid pathology (86). Although this was an Alzheimer’s study and
curcumin was not the focus, it demonstrates the role curcumin plays in the
regulation of actin organization. In another study, curcumin affected the
formation of actin stress fibers which helps to suppress the intra-hepatic
metastasis in an orthotopic implantation model (101).

Curcumin and Dendritic Cells
Outside of the work published from this study, there is only one article to
date that explores the role of curcumin dendritic cells. The authors show
curcumin inhibits the immuno-stimulatory function of murine bone marrowderived dendritic cells (69). The authors show that at non-toxic concentrations,
curcumin is a potent inhibitor of DC maturation. Curcumin suppresses the
expression of surface maturation markers CD80, CD86 and MHC class II in a
concentration dependent manor and reduces the production of IL-12 and other
pro-inflammatory cytokines IL-6, IL-1β and TNF-α in LPS-matured DCs.
Studies have chronicled the effects of curcumin on antigen presenting cells other
than dendritic cells. An in vivo model of murine latex allergy shows CD80 and
CD86 levels are reduced on lung B cells treated with curcumin (73). Another
study reports reduced CD80 and CD86 expression on macrophages treated with
curcumin (121). The immunomodulatory properties of curcumin also extend to its
effects on cytokine production in dendritic cells and other antigen presenting cells
(1, 44, 66, 69, 152). Curcumin reduced levels of IL-12, IL-6, IL-1β, TNF-α in
murine DCs, monocytes and macrophages. Pre-treatment with curcumin also
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inhibits transcription of IL-1α, IL-1β, IL-2, IL-6, IL-10 and TNF-α mRNA in rat liver
(40). In this study we investigate the effect of curcumin on human dendritic cell
maturation by pre-treating the cells with curcumin and then inducing maturation
with immune stimulants.

Significance of the Study
A study by Kim et al. reveals that curcumin impairs the immunostimulatory
function of murine dendritic cells (69), but the effects of curcumin on human
dendritic cells remain unknown. In this study we investigate the effects of
curcumin on human monocyte-derived DC maturation and function. Dendritic
cells direct the adaptive immune response to pathogens and allergens so we
hypothesize they play a critical role in mediating curcumin’s systemic effects. We
examine effects of curcumin on human dendritic cell maturation and function.
Modulating the DC response could provide an effective approach to treat and
control unwanted inflammation and could provide an effective approach to
treating inflammatory diseases. Elucidation of the underlying mechanism of
curcumin modulation will have a direct impact on allergic disease control as
recent studies point to its great potential for protection against lung diseases and
allergic asthma (71, 73, 110, 131, 144). Curcumin shows promise as an
immunomodulatory compound for the treatment of allergic diseases. Kobayashi
et al. reports that curcumin inhibits IL-5, GM-CSF and IL-4 production and inhibits
the proliferation and IL-2 production in lymphocytes obtained from atopic
asthmatics in response to Dermatophagoides farinea (71). Curcumin diminishes
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the Th2 response, reduces lung inflammation and reduces eosinophilia in a
murine model of latex allergy (73) and also reduces histamine release from rat
basophilic leukemia cells (131). In guinea pigs it is shown to attenuate airway
hyper-responsiveness (110). Curcumin presents itself as an interesting molecule
for further investigation. The findings of this study provide novel treatment and
control strategies for allergic diseases. Due to its low toxicity, curcumin would
offer itself as a safe alternative to non-steroidal anti-inflammatory drugs (NSAIDs)
and other inflammatory drugs currently available.
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GOALS AND OBJECTIVES

Purpose
The purpose of this study is to examine the effect of curcumin on immature
human dendritic cell development and function in response to external stimulants
that mimic infection and stimulate cell maturation or activation. This study utilizes
in vitro cultures of primary dendritic cells obtained from a number of donors
assumed to be in good health. Lipopolysaccharide (LPS),
polyinosinic:polycytidylic acid (poly I:C) or tumor necrosis factor alpha (TNF-α)
were used to stimulate or induce DC maturation through independent cellular
pathways.

Hypothesis
Curcumin has potent anti-inflammatory properties and prevents the
immunostimulatory function of murine dendritic cells. We hypothesize that the
same is true for human dendritic cells. We expect curcumin will prevent DC
maturation in response to a variety of stimulants and impede cell function.
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Specific aims
Aim 1: To determine the effect of curcumin on human mdDC maturation in
response to immune stimulants.


Does curcumin affect visual signs of DC maturation such as cell
morphology and homotypic clustering?



Can curcumin alter the expression of the surface markers on iDCs?



Does curcumin affect the level of expression of the surface markers on
DCs in response to immune stimulants? If so, is it dependent on the
pathway propagated by the stimulant?



Can curcumin alter cytokine production in stimulated cells?

Model

mdDC
primary culture
No stimulation (24 hrs)

Independent
Variables

Curcumin
pre-treatment (1hr):
• 0 µM (DMSO)
• 20 µM (7.4µg/ml)
• 30 µM (11.1µg/ml)

LPS stimulation (24 hrs)
poly I:C stimulation (24hrs)
TNF-α stimulation (24hrs)

•
•
•

Dependent
Variables

•

Cell morphology
Homotypic cluster formation
Surface marker expression:
(CD86, CD83, HLA-DR, CD40,
CD54)
Cytokine secretion:
(IL-12p70, IL-10, IL-6, TNF-α,
IFNγ)

Figure 2. Aim 1 experimental outline. Designed to investigate the effects of curcumin on
human mdDCs with and without stimulation. Dashed boxes represent independent variables
and solid boxes represent dependent variables.
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Aim 2: To determine the effect of curcumin on human mdDC function in the
presence of immune stimulants.


Does curcumin affect iDC endocytosis?



Does curcumin affect endocytosis of stimulated DCs?



Does curcumin affect DC chemokine secretion and chemokine receptor
expression?



Does curcumin affect DC chemotaxis?



Does curcumin affect the ability of DCs to induce proliferation of allogeneic
donor CD4+ T cells in co-culture?



How does curcumin affect the phenotype of proliferated T cells in coculture?

Model

DC primary
culture

Allogeneic
DC-TC
co-culture

No stimulation (24 hrs)

Independent
Variables

Curcumin
pre-treatment (1hr):
• 0 µM (DMSO)
• 20 µM (7.4µg/ml)
• 30 µM (11.1µg/ml)

LPS stimulation (24 hrs)
poly I:C stimulation (24hrs)

Dependent
Variables

•
•
•

Endocytosis
Chemotaxis
Chemokine and chemokine
receptor expression

•
•

T cell proliferation
T cell phenotype

Figure 3. Aim 2 experimental outline. Designed to examine the effects of curcumin on stimulated
DC function.
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Aim 3: To determine the effect of curcumin on actin rearrangement in human
mdDCs.


Does curcumin affect the expression of actin and actin pathwayassociated proteins in human DCs?



Does curcumin affect actin polymerization and cytoskeleton
rearrangement in human DCs?



Does the inhibition of actin result in similar functional observations to that
of curcumin?

Model

Independent
Variables

DC primary
culture

Curcumin
pre-treatment (1hr):
• 0 µM (DMSO)
• 20 µM (7.4µg/ml)
• 30 µM (11.1µg/ml)

Dependent
Variables

No stimulation (24 hrs)
LPS stimulation (24 hrs)

•
•
•
•
•

Microarray analysis of total RNA
Confocal imaging of actin
Confocal imaging of actin pathwayassociated proteins
Western blot of actin pathway molecules
Functional assay using actin inh bitor
(endocytosis assay)

Figure 4. Aim 3 experimental outline. Designed to examine the effect of curcumin on the actin
cytoskeleton in dendritic cells.
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MATERIALS AND METHODS
Materials
Curcumin (from Curcuma longa) was obtained from Sigma Aldrich (St. Louis,
MO) and dissolved in DMSO (11mg/ml). Buffy coats were obtained from Florida
Blood Services (St. Petersburg Florida). Donors in good health and ranging in
age from 18 to 50 were used for the study (Table 1). The cell isolation reagents
CD14 microbeads and naïve CD4+ T cell isolation kit were obtained from Miltenyi
Biotec (Auburn, CA). For cell isolation and culture, Histopaque®-1077 and was
obtained from Sigma Aldrich and recombinant human cytokines GM-CSF and IL4 were obtained from PeproTech (Rocky Hill, NJ). All other cell culture reagents
were obtained from GIBCO Invitrogen (Carlsbad, CA). LPS, poly I:C and PHA
were obtained from Sigma Aldrich (St. Louis, MO). CFSE and Alexa-647
conjugated dextran (molecular weight 10,000) were obtained from Molecular
Probes Invitrogen (Carlsbad, CA). LINCOplex Multiplex cytokine assay kits were
purchased from Millipore (Temecula, CA). All antibodies used for flow cytometry
CD11c, HLA-DR, CD40, CD86, CD83 and CD54 were obtained from BD
Biosciences (San Jose, CA). The antibodies used for western blotting: CD83,
CD86 and HLA-DR were obtained from Santa Cruz Biotechnology (Santa Cruz,
CA). Chemokines CCL19 and CCL21 were obtained from PeproTech (Rocky Hill,
NJ).
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Table 1. Age and gender of donors used in the study
Donor ID

Age

Gender

13

31

Female

14

24

Female

A

61

Female

B

26

Male

C

20

Female

D

21

Female

E

21

Male

F

21

Male

G

42

Male

H

28

Male

I

59

Female

J

50

Female

K

42

Female

Monocyte Isolation and culture
In the human body DCs are generated via multiple pathways. They can be
derived from CD34+ stem cell precursors or derived from blood monocytes (123).
Monocyte-derived DCs generated from CD14 + cells obtained from peripheral
blood are phenotypically and functionally similar to circulating DCs in the human
body (47, 134). For the purposes of this study mdDCs provide a suitable in vitro
model. CD14+ monocytes were isolated and cultured as described by Picki et al.
(105). Leukocytes were extracted from buffy coats using Histopaque-1077.
Monocytes expressing CD14 were positively selected with magnetic microbeads.
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Purity (>90%) was verified by staining with anti-CD14 antibodies and analyzing
by flow cytometry. Cells were cultured at 1 × 106 cells/ml in complete RPMI (2%
L-Glutamin,10% fetal bovine serum, 1% penicillin/streptomycin, 10mM Hepes,
non-essential amino acids and 5mM sodium pyruvate) with 20 ng/ml each rh IL-4
and GM-CSF for five days at 37°C in an atmosphere of 5% CO2 and 95% air,
(supplementing at day three with fresh medium). On day 5, most cells express an
immature DC phenotype expressing high CD11c, low CD40, CD86, CD83 and
HLA-DR (113) (Figure 6). Mature DCs were induced by adding either LPS, Poly
I:C or the cytokine TNF-α to the culture for 24hours (23). The mature phenotype
was confirmed by surface marker expression (high CD11c, CD40, CD86, CD83
and HLA-DR) measured by flow cytometry (Figure 6). DCs were identified by
forward and side scatter morphology; those cells were gated and subjected to
further analysis to quantify marker expression (Figure 5).

Figure 5. Dendritic cell morphology gating based on forward and side scatter from flow cytometry
after culture with GM-CSF and IL-4. 93.6 percent of the total events recorded were assumed to
be DCs.
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Un-stimulated Cells

Stimulated Cells

Unstained cells

CD11c

Stained cells

Immature DC Phenotype:
CD11c+
HLA-DR+ (low)
CD83CD86+ (low)
C40+ (low)

HLA-DR

Mature DC Phenotype:
CD11c+
HLA-DR+ (high)
CD83+
CD86+ (high)
CD40+ (high)

CD83

CD86

CD40

Figure 6. Surface marker expression on cultured immature and mature DCs. Cells display both
immature and mature dendritic cell phenotype under the specified culture conditions. Surface
marker expression determined by antibody staining of cell surface markers and flow cytometry
analysis. The mature DCs express higher intensity surface marker expression than immature
DCs.
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T cell isolation and culture
CD4+ T cells were isolated from the non-CD14 expressing fraction remaining
after monocyte depletion and cultured in complete RPMI. The untouched cells
were negatively selected using magnetic beads (Miltenyi Biotec).

Curcumin treatment and cell stimulation
Curcumin, an ingredient of Indian curry powder, supplied as a powder (Sigma) is
a polyphenolic compound insoluble in water. Dimethylsulfoxide (DSMO) is used
as a solvent in this study and therefore used as a control. Curcumin was added
to iDC culture (1 × 106 cells/ml and 3 ml/well in 6-well plates) at the indicated
concentrations (20µM or 30µM in most experiments). Cultures were incubated for
1 hour at 37°C in an atmosphere of 5% CO2 and 95% air after which a stimulant
(LPS, Poly I:C or TNF-α) was added to the appropriate wells. Control wells
received no stimulants. Cultures were incubated overnight at 37ºC and 5% CO2
and 95% air. Curcumin toxicity was assessed by 7AAD incorporation and
measured by flow cytometry. Cells were found to be 95% (± 0.06) viable after 24
hours of culture under all conditions listed above.

Cell viability by flow cytometry
In order to assess the toxicity of curcumin in DC culture after a prolonged period,
cell viability was assessed. Cells were collected and stained with 7-aminoactinomycin D (7AAD), a nuclear dye, and analyzed by flow cytometry.7AAD is
used to discriminate living cells from dead cells. Live cells with intact membranes
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will exclude the dye, while damaged cells will allow the dye to enter the cell
(114). The gating strategy was similar to that mentioned above (Figure 5).
Measurements were taken at three time points using six concentrations of
curcumin. The 30µM concentration is the highest at which viability does not fall
below 90% after 12 hr culture (Figure 7). The 10µM concentration did not show
significant changes in preliminary studies and so was not included in this work.
Only the non-toxic 20µM or 30µM concentrations of curcumin were used for the
experiments in this study.
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Figure 7. Dendritic cell viability measured by 7AAD staining and flow cytometry after 3 hrs, 12 hrs
and 24 hrs of culture with curcumin at various concentrations.

Surface marker analysis by flow cytometry
Cells were collected, washed, re-suspended (1 × 106 cells/ml) and stained with
fluorochrome-conjugated antibodies specific for DC surface markers CD11c,
HLA-DR, CD40, CD86, CD83 and CD54. After staining, cells were washed and
fixed with 4% paraformaldehyde (PFA) then re-suspended in staining buffer,
protected from light and stored at 4°C until flow cytometry analysis. Cells were
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analyzed using the Becton Dickenson (BD) Canto II with HTS sampler and BD
FACSDiva™ software. Figures were generated using FlowJo software (Tree Star
Inc.)

Multiplex bead assay
Cytokines produced by DCs in culture were measured by multiplex bead assay
(Millipore). Culture supernatant was collected, centrifuged to remove any
particulates and stored at -20°C. Cytokine levels measured from the supernatant
using the LINCOplex human multiplex assay. Six cytokines (IL-12p70, IL-10, IL6, IL-8, TNFα and IFNγ) and two chemokines (IP-10 and fractalkine) were
measured from DC supernatant using this method. Six cytokines (IL-2, IL-4, IL-6,
IL-10, IL-13 and IFNγ) were measured from DC – TC co-culture supernatant after
the mixed lymphocyte reaction (MLR). Assays were performed in duplicate
according to the manufacturer’s instructions. In summary, samples were diluted
with an equal volume of medium and 25µl aliquots were used per assay well.
Culture medium was used as the blank for the assay. Samples were incubated
with antibody coated capture beads for 1hr, wells were washed and the cocktail
of biotin labeled anti-human cytokine antibodies were added to all wells. After a
2hr incubation at room temperature streptavidin-phycoerythrin was added for 30
minutes. Samples were analyzed using the Luminex 100 IS system and IS 2.3
software (Luminex, Austin, TX). Data was generated as mean fluorescence
intensity (MFI) for each cytokine. Standard curves were generated using 5
parameter logistic regression based on known concentrations of the recombinant
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cytokines provided by the manufacturer. This was used to calculate the
concentration (pg/ml) for the samples that were assayed.

Homotypic clustering
Dendritic cell clustering is a hallmark of activated or mature cells. It allows cells to
communicate with each other as well as responder cells such as T cells and B
cells Cell to cell contact is critical for antigen presentation and the propagation of
the adaptive immune response (31). The size and density of the cluster may be
indicative of the activation state of the cells. Strongly activated cells form larger
and more dense clusters than weakly activated or immature cells. Clusters were
observed by light microscopy at low power magnification (4x). Images were
recorded using an Olympus digital camera.

Western Blotting
Cells were collected, washed and lysed using NP-40 lysis buffer containing
protease and phosphatase inhibitors. Proteins were quantified using a BCA
protein assay kit and 100µg loaded onto an SDS-PAGE gel. After
electrophoresis, proteins were transferred onto a PVDF membrane by
electrophoresis. The membranes were blocked using 5% non-fat milk for 1 hr at
room temperature and subsequently probed with the appropriate antibodies in
5% bovine serum albumin (BSA) buffer overnight at 4°C. The membranes were
washed and incubated with horseradish-peroxidase (HRP)-conjugated secondary
antibodies. The bands were visualized by incubating the membranes in West
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Pico chemiluminescent reagent (Thermo Scientific) for 5 minutes protected from
light and exposing the membranes to x-ray film (Kodak).

Endocytosis assay
Immature DCs have the intrinsic ability to capture foreign materials by
endocytosis. Stimulated or mature DCs do not possess this ability (113). This
inherent property is used as a measure of DC maturity. Treated and stimulated
cells were collected, washed and incubated with 1mg/ml (per 1×106 cells) Alexa
647 conjugated dextran at either 4ºC or 37ºC for 1 hour. Cells were washed with
cold PBS and either analyzed by flow cytometry or plated on gelatin coated cover
slips and imaged by confocal microscopy. The change in mean fluorescence
intensity (MFI) is calculated as the difference between the MFI of 37ºC and 4ºC
cultures.

Chemotaxis assay
Another measure of DC function is its ability to migrate towards chemoattractants (81). Mature DCs are more motile than iDCs. Treated and stimulated
cells were collected, counted and re-suspended at a concentration of 1 x 106
cells/ml. 50µl of cell suspension was placed in the upper chambers of 5µm pore
size polycarbonate filter inserts in a 96 well microchemotaxis plate (Chemicon).
The lower chambers contained 40µl of either CCL19 or CCL21 in 150µl of
medium. Control wells had medium only. Input wells (in triplicate) contained 1 x
104 cells in the lower chambers without chemokines. Cells were incubated at
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37ºC and 5% CO2/95% air overnight. Migration was stopped by the removal of
the inserts. 1 x 104 polystyrene beads were added to each well (lower chamber)
and analyzed by flow cytometry. The number of cells in each sample and input
was calculated using the following equation: Number of cells/well = (number of
cell events ÷ number of bead events) x 104. Input cells = average [number of
input cells/well x 5 (dilution factor)]. The percentage migration for each sample
(% input) is determined by the following equation: Percent migration = (migrating
cells ÷ input cells) x 100.

Mixed lymphocyte reaction
Mature DCs are able to stimulate proliferation of allogeneic T cells and induce a
helper response. In order to determine the effect of curcumin on DC function
after stimulation, T cell proliferation and polarization was assayed using a mixed
lymphocyte reaction. In order to measure proliferation, T cells were loaded with
an intracellular dye carboxyfluoroscein succinimidyl ester (CFSE). CFSE
passively diffuses into cells and reacts with amines in the cytoplasm forming
highly fluorescent conjugates. As the cells divide the conjugates are distributed to
the daughter cells. Fluorescence intensity was measured by flow cytometry, with
each generation of cells emitting approximately half the fluorescence intensity of
the parent. CFSE labeling of CD4+ T cells was carried out according to published
procedures (108). Cells were suspended in 1ml PBS containing 5% (v/v) FBS.
1.1µl of the CFSE stock (5µM) was diluted in 110µl of PBS and then quickly
mixed with the cell suspension. After a 5 minute incubation at room temperature,
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the reaction was stopped by adding ten volumes of room temperature PBS
containing 5% (v/v) FBS and centrifuging at 300 × g for 5 minutes at 20ºC. Cells
were washed twice and re-suspended in complete medium (1 × 106 cells/ml). The
DC-T cell co-culture was set up at a ratio of 1:16. Curcumin treated and
stimulated DCs were removed from culture and placed in 96 well plates in
triplicate (6.25 × 103 cells in 100µl per well). 100µl of T cells were added to each
well and cultures incubated at 37ºC and 5% CO2 /95% air for 5 days.
Unstimulated T cells were used as the negative control, mitogen
(phytohemagultinin: PHA at a concentration of 5µg/ml) stimulated T cells were
used as the positive control. CFSE fluorescence intensity was measured by flow
cytometry using the BD Canto II with HTS attachment and BD FACS Diva
software.

Immunofluorescence labeling
Cells were collected, washed and fixed with 4% PFA. For intracellular staining,
cells were permeablized with CytoFix/CytoPerm solution (BD Pharmingen). Nonspecific antigens were blocked by using staining buffer containing FBS. The
staining buffer also contained saponin (BD PermWash buffer) which maintains
cell permeabilization. Cells were incubated with the appropriate antibodies,
washed thoroughly and mounted in a glycerol-based mounting medium that
contains DAPI. Slides were stored at 4ºC, protected from light until imaging.
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Microscopy
All bright field images were captured using the 4x objective of an Olympus IX71
inverted fluorescent microscope with an attached DP70 camera. Fluorescent
images were captured using either the 63x or the 40x objective of a Leica
scanning confocal microscope.

RNA extraction from human DCs
Monocyte-derived DCs obtained from human peripheral blood were placed in
experimental groups, treated with curcumin and stimulated with LPS (Figure 8).
Total RNA was extracted from cells using the RNeasy isolation kit (Qiagen) as
per the manufacturer’s instructions. RNA was quantified by optical density
measurements and its purity and integrity determined by agarose gel
electrophoresis of samples stored at room temperature and samples heated to
42ºC for 1 hr and 70ºC for 10 minutes.

Microarray
All microarray experiments and analysis were carried out at the H. Lee Moffitt
Cancer Center Microarray Core Lab. Affymetrix HG U133 Plus 2 array
GeneChips were used for the experiment. A separate chip was used for each of
the four samples (Figure 8). Isolated RNA was biotinylated as described in the
Affymetrix GeneChip Expression Analysis Manual (Affymetrix). 5µg total RNA
was converted to double stranded DNA using 100pmol of an oligo-dT primer that
contains a T7 promotor. The resulting cDNA was used in a transcription reaction
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with biotinylated nucleotides. The product of this reaction was fragmented and
hybridized to the GeneChips. After 16 hours of hybridization, the chip was
washed and stained with streptavidin-phycoeryhtrin and then read using an
Affymetrix GeneChip scanner. Data was processed using the GeneChip
Operating Software (GCOS) Microarray Suite 5.0 (Affymetrix). Based on criteria
set by Affymetrix GCOS software, only genes that are considered to be “present”
will be used for further analysis. “Present” calls are made by comparing the 11
perfect matches and mismatches for each probe set. The data generated was
normalized to control genes and filtered by present and absent calls or by gene
increase or decrease calls. Genes were annotated using software provided by
the Microarray Core Facility. To identify cellular pathways affected by curcumin
treatment and LPS stimulation, the data was examined using Ingenuity Systems
Pathways Analysis 6.3 (Ingenuity Systems®, www.ingenuity.com) software which
categorizes identified genes based on biological function and signaling pathways.
Canonical Pathways Analysis identified the pathways from the Ingenuity
Pathways Analysis library of canonical pathways that were most significant to the
dataset. The significance of the association between the dataset and the
canonical pathway was measured in 2 ways: 1) A ratio of the number of genes
from the dataset that map to the pathway divided by the total number of
molecules that exist in the canonical pathway is displayed. 2) Fischer’s exact
test was used to calculate a p-value determining the probability that the
association between the genes in the dataset and the canonical pathway is
explained by chance alone.
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Model

Independent variable

Dependent variable

Add DMSO for 12hr

Add curcumin (20µM)
dissolved in DMSO for 12hr
RNA isolation

md-iDCs
Add curcumin (20µM)
dissolved in DMSO for 1hr
then add LPS for 11hrs

Add DMSO for 1hr then
add LPS for 11hrs
Microarray
Figure 8. Experimental outline for microarray analysis

Statistical analysis
In this study a 4 x 3 factorial design was used. All values are reported as mean
and standard error of the mean (SEM). Most data was transformed using a base
10 logarithm to ensure normal distribution, with the exception of viability and
proliferation values in which case the raw data was reported. All donors
displayed similar trends in response to treatment and stimulation, however due to
individual variation there were differences in the magnitude of the values. Paired
t-tests (repeated measures) for planned comparisons were conducted.
Significance was determined using a modified Bonferroni correction (55). Each
test of significance was ranked and the range of observed p values were
compared to critical alpha values a (a = alpha 0.05 divided by the number of
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planned comparisons). Values are presented as the average of six donors. Error
bars represent SEM. All statistical calculations were performed using the
Statistical Package for Social Sciences (SPSS version 15). Figures were
generated using GraphPad Prisim (version 3.03). A concentration dependent
reduction in values was observed in almost all cases. Though significance was
calculated for only the 20µM concentrations, the change in values of the 30µM
concentration compared with the control were therefore thought to be significant
as well.
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RESULTS
Aim 1: Curcumin Prevents Dendritic Cell Maturation

Curcumin Affects DC Morphology
Dendritic cells have a characteristic morphology. They are slightly irregular
in shape and have finger-like projections or dendrites that increase their surface
area to maximize cell-cell contact. Curcumin appears to cause the cells to
become more spherical and to lose their dendrites (Figure 9). This change is
evident in both the absence and presence of LPS. Similar effects were noted for
poly I:C and TNF-α stimulated cells (data not shown).
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DMSO

LPS

DMSO

Cur 20µM

Figure 9. Curcumin affects cell morphology. Cells were cultured for 24hs with or without curcumin
(20µM) and LPS (1µg/ml). Images were captured using an inverted light microscope with a 40x
objective lens. Red arrows indicate cell dendrites. Images are from a single representative of
eight donors.

Curcumin Prevents Homotypic Cluster Formation
Homotypic cluster formation correlates directly with phenotypic DC
maturation. Stimulated or mature DCs will form clusters due to their increased
marker expression and enhanced motility. In order to determine the effects of
curcumin on DC clustering, cells were cultured in the presence of curcumin for 24
hrs and then examined under an inverted light microscope using a low power
objective (4x). Curcumin prevents DCs from forming large, dense clusters
characteristic of mature DCs in response to stimulants such as LPS, poly I:C and
TNF-α (Figure 10). This effect is concentration dependent as the 30µM
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concentration abrogates cluster formation completely. There are some clusters
formed in the experimental groups that received 20µM curcumin and were
stimulated with poly I:C and TNF-α, but these were much smaller than those
formed in the similarly stimulated control groups. The clusters formed in
response to LPS were larger and more dense that those formed in response to
poly I:C and TNF-α.
No Stim

LPS

Poly I:C

TNF-α

DMSO

Cur 20µM

Cur 30µM

Figure 10. Curcumin prevents homotypic clustering of stimulated DCs. Cells were cultured for 24
hrs with or without curcumin (20µM or 30µM) and LPS, poly I:C or TNF-α added to the
appropriate wells. Images were captured using an inverted light microscope with a 4x objective
lens. Images are of a single representative of eight donors.
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Curcumin Reduces Surface Marker Expression
Immunofluorescence labeling and flow cytometry was used to determine
the effects of curcumin on surface marker expression. Cells were evaluated
using two concentrations of curcumin (20µM and 30µM) and three immune
stimulants (LPS, poly I:C and TNF-α). Data is reported either as percentage
positive cells or mean fluorescence intensity (MFI) of all donors (n = 8). Table 2
shows p values of significance for each experimental group assessed. A similar
number of cells were stained for the surface markers CD11c, HLA-DR, CD83,
CD86 and CD40 and analyzed in each experimental group. In order to determine
the effects of surface marker expression on iDCs, cells were treated with
curcumin for 24 hrs and no stimulant was introduced into culture. There was no
significant change in surface marker expression for all donors (Figure 12). In
figure 11 the unstimulated cells treated with 30µM curcumin show reduced CD86
expression, this was only seen in this donor and not the trend across all donors.
In the presence of all three stimulants, the cells that were treated with curcumin
had reduced expression of CD83, CD86, CD54 and CD40 when compared to
stimulated controls (Figures 11, 12). HLA-DR surface expression was not
significantly affected by the 20µM concentration of curcumin; however the 30µM
concentration of curcumin showed significant results (Figure 11).
Immunofluorescece staining shows that curcumin-treated DCs retain some HLADR in the cytoplasm (Figure 13a). Western blot shows curcumin-treated DCs
have a lower level of expression of the antigen presenting molecules CD86,
CD83 and HLA-DR (Figure 13b). All cells expressed high levels of CD11c, but by
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measure of fluorescence intensity, the LPS and TNF-α stimulated cells treated
with 30µM concentrations and the LPS stimulated cells 20µM showed
significantly reduced expression of CD11c compared to stimulated controls.
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TNFα
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Figure 11. Curcumin reduces dendritic cell surface marker expression in stimulated cells. Flow
cytometry histograms are a single representative of 6 donors. The yellow-green line represents
the unstained cells and used to designate the negative population.
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Figure 12. Curcumin reduces dendritic cell surface marker fluorescence intensity in stimulated
cells. The y-axis represents the average log10 mean fluorescence intensity (MFI) ± SEM for 8
donors. * indicates significance by one-tailed t-test of planned comparisons p < critical alpha
value.
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Table 2. Significance of curcumin effects on surface marker expression (mean fluorescence
intensity): Comparison of DMSO vs. Curcumin (Cur 20µM)
Mean
(DMSO)

Mean
(Cur 20µM)

Critical
p value

Observed
p value

Significance

CD11c

4.830 ± 0.122

4.715 ± 0.134

0.0500

0.0051

Yes

HLA-DR

3.285 ± 0.350

3.279 ± 0.346

0.0500

0.4518

No

CD86

3.916 ± 0.120

4.010 ± 0.170

0.0500

0.0762

No

CD83

2.872 ± 0.235

2.730 ± 0.277

0.0500

0.0099

Yes

CD40

3.071 ± 0.488

3.132 ± 0.442

0.0500

0.0623

No

CD54

4.532 ± 0.190

4.377 ± 0.246

0.0500

0.0078

Yes

CD11c

5.024 ± 0.042

4.842 ± 0.075

0.0085

0.0009

Yes

HLA-DR

3.544 ± 0195

3.542 ± 0.211

0.0170

0.1326

No

CD86 *

5.013 ±0.102

4.317 ± 0.145

0.0085

0.0000

Yes

CD83

3.868 ± 0.152

3.260 ± 0.208

0.0085

0.0001

Yes

CD40

3.793 ± 0.222

3.399 ± 0.336

0.0085

0.0005

Yes

CD54 *

5.052 ± 0.087

4.792 ± 0.107

0.0085

0.0000

Yes

CD11c

4.920 ± 0.076

4.621 ± 0.105

0.0170

0.0019

Yes

HLA-DR

3.412 ± 0.167

3.319 ± 0.197

0.0085

0.0013

Yes

CD86 *

4.644 ± 0.514

4.120 ± 0.446

0.0170

0.0000

Yes

CD83

3.542 ± 0.088

2.873 ± 0.111

0.0170

0.0004

Yes

CD40

3.854 ± 0.595

3.454 ± 0.589

0.0170

0.0011

Yes

CD54

4.659 ± 0.516

4.307 ± 0.615

0.0170

0.0011

Yes

CD11c

4.926 ± 0.093

4.744 ± 0.076

0.0250

0.0022

Yes

HLA-DR

3.415 ± 0.198

3.409 ± 0.190

0.0250

0.4483

No

CD86

4.173 ± 0.523

4.006 ± 0.490

0.0250

0.0024

Yes

CD83

3.445 ± 0.106

2.995 ± 0.106

0.0250

0.0006

Yes

CD40

4.463 ± 0.633

4.282 ± 0.569

0.0250

0.0188

Yes

CD54

3.884 ± 0.799

3.679 ± 0.819

0.0250

0.0033

Yes

No Stimulation

LPS

Poly I:C

TNF-α

* observed p values were less than 0.0001
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Figure 13. Curcumin reduces the expression of the antigen presentation molecules.
Immunofluorescence labeling of fixed and permeabilized DCs (A) and western blot of whole cell
lysate (B) showing reduced expression of marker expression in the presence of curcumin and
LPS.
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Curcumin Reduces Cytokine Production
Cytokine production by dendritic cells is indicative of maturation.
Cytokines produced will begin the cascade of immune reaction and induce cell –
cell interactions which initiate the adaptive response. In order to assess the
effects of curcumin on cytokine production, iDCs were treated with two
concentrations of curcumin and stimulated with either LPS or poly I:C. Culture
supernatants were collected and analyzed by multiplex bead assay. IFNγ, IL12p70, the immunomodulatory cytokine IL-10 as well as pro-inflammatory
cytokines IL-6, IL-8 and TNF-α were measured. The assay was carried out in
duplicate and the average of 6 donors is represented in figure 14. Due to the
innate variations in donor response to the stimulants, the data are averaged and
represented as log10 concentration. Table 3 shows the p value significance for
the curcumin effects noted in this assay. Table 4 shows the p value significance
of the stimulant effects. Characteristically low levels of all cytokines were
produced by non-stimulated cells. These levels were not affected by curcumin at
either concentration. Stimulation with LPS and poly I:C resulted in substantial
production of all cytokines. IL-10, IL-6 and IL-12p70 were significantly reduced in
the curcumin treated cells stimulated with LPS and poly I:C in a concentration
dependent manor. These levels were more or less reduced to the levels of the
iDC cells that received no stimulation (Figure 14). In cells stimulated with LPS,
higher levels of IL-8 were produced than the poly I:C stimulated groups. Some
values were outside of the dynamic range of the assay. The 20µM curcumin
concentration significantly increased IL-8 production in poly I:C stimulated cells
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above the stimulated controls. Due to the fact that the LPS-stimulated 20µM
curcumin treated cells were out of the range of the assay, the curcumin effects
were not significant. The 30µM concentration did not reduce levels below the
untreated control in response to either stimulant. There was a significant increase
in IL-8 levels however in the unstimulated control group treated with curcumin
(20µM). The level of IFNγ produced in this assay was minimal. In LPS-stimulated
cells, curcumin caused a significant reduction in the amount of this cytokine that
was produced. No significant reduction was observed in the poly I:C stimulated
group. Stimulated DCs showed significantly reduced TNF-α levels in when
curcumin was present. Though this reduction was concentration dependent,
unlike with the other cytokines, the TNF-α levels were not reduced to that of the
unstimulated controls (Figure 14).
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Figure 14. Curcumin reduces cytokine production by human DCs in response to stimulants. Cells
were cultured in the presence of curcumin (20µM and 30µM) and stimulated with either LPS or
poly I:C. Data is represented as log (base 10) concentration and the average of 6 donors. Error
bars are SEM and * indicates significance (p < critical alpha)
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Table 3. Significance of curcumin effects on cytokine production: Comparison of DMSO vs. Cur
20µM
Mean
(DMSO)

Mean
(Cur 20µM)

Critical p

Observed p

Significant

IL-10

1.196 ± 0.454

0.977 ± 0.459

0.025

0.003

Yes

IL-12p70

0.477 ± 0.000

0.477 ± 0.000

-

-

-

IL-6

1.194 ± 0.676

1.099 ± 0.831

0.05

0.199

Yes

IL-8

2.022 ± 0.428

2.553 ± 0.899

0.025

0.0078

Yes

TNF-α

1.234 ± 0.113

0.869 ± 0.548

0.025

0.0665

No

IFNγ

0.627 ± 0.423

0.477 ± 0.000

0.05

0.1753

No

IL-10

3.453 ± 0.825

2.078 ± 1.011

0.017

0.0005

Yes

IL-12p70

2.626 ± 0.983

0.964 ± 0.596

0.025

0.002

Yes

IL-6

4.132 ± 0.257

3.372 ± 0.926

0.025

0.009

Yes

IL-8

4.162 ± 0.306

4.314 ± 0.022

0.05

0.097

No

TNF-α

4.157 ± 0.388

3.623 ± 0.398

0.017

0.0065

Yes

IFNγ

1.557 ± 0.764

0.832 ± 0.612

0.017

0.0074

Yes

IL-10

1.705 ± 0.394

1.151 ± 0.585

0.05

0.001

Yes

IL-12p70

2.467 ± 1.296

0.865 ± 0.809

0.05

0.003

Yes

IL-6

3.309 ± 0.497

2.285 ± 0.808

0.017

0.001

Yes

IL-8

3.309 ± 0.497

3.630 ± 0.282

0.017

0.0007

Yes

TNF-α

2.839 ± 0.918

2.362 ± 0.702

0.05

0.0145

Yes

IFNγ

0.780 ± 0.424

0.557 ± 0.225

0.025

0.1376

No

No Stimulation

LPS

Poly I:C
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Table 4. Significance of stimulant effects: Comparison DMSO (No stim) vs. Stimulant (Stim)
Mean
(No Stim)

Mean
(Stim)

Critical
p value

Observed
p value

Significance

IL-10

1.196 ± 0.454

3.453 ± 0.825

0.025

0.0000

Yes

IL-12p70

0.477 ± 0.00

2.626 ± 0.983

0.025

0.0000

Yes

IL-6

1.194 ± 0.676

4.132 ± 0.257

0.025

0.0000

Yes

IL-8

2.022 ± 0.428

4.162 ± 0.306

0.025

0.0000

Yes

TNFα

1.234 ± 0.113

4.157 ± 0.388

0.025

0.0000

Yes

IFNγ

0.627 ± 0.423

1.557 ± 0.764

0.025

0.0210

Yes

IL-10

1.196 ± 0.454

1.705 ± 0.394

0.05

0.0010

Yes

IL-12p70

0.477 ± 0.00

2.467 ± 1.296

0.05

0.0015

Yes

IL-6

1.194 ± 0.676

3.309 ± 0.497

0.05

0.0005

Yes

IL-8

2.022 ± 0.428

3.309 ± 0.497

0.05

0.0035

Yes

TNFα

1.234 ± 0.113

2.839 ± 0.918

0.05

0.0010

Yes

IFNγ

0.627 ± 0.423

0.780 ± 0.424

0.05

0.2719

No

LPS*

Poly I:C

* Observed p values were less than 0.0001
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Aim 2: Curcumin Prevents Dendritic Cell Function

Curcumin Reduces Endocytosis
Endocytosis is a feature of immature dendritic cells which are usually
found in the periphery. Maturing migrating DCs lose their ability to edocytose.
Therefore, the test of endocytic capacity is thought of as the gold standard in
assessing DC maturity as a measure of function. In order to assess the effects of
curcumin on iDC endocytosis, cells were cultured in the presence of curcumin for
24hrs and then cultured with fluorescently labeled dextran (MW 10,000). Dextran
uptake was measured by flow cytometry and confocal microscopy. Data is
represented as the average change in mean fluorescence intensity (MFI) of six
donors (Figure 15b). Confocal microscope imaging of a representative donor is
shown in figure 15a. The significance of the effects of curcumin are shown in
table 4 and the significance of stimulant effects are shown in table 5.
Curcumin prevents iDCs from taking up dextran in a concentration
dependent manner (Figure 15b). In the curcumin treated cells, dextran
accumulates along the cell membrane and not throughout the cytoplasm as in
the untreated control (Figure 15a). LPS stimulated cells show characteristically
reduced dextran uptake. The level of endocytosis for both LPS and poly I:C
stimulated DCs were significantly reduced when compared to the unstimulated
control (open bars in figure 15b). Pre-treated stimulated DCs show dextran
uptake similar to that of the unstimulated pre-treated controls (black and hatched
bars in Figure 15b). Similar to curcumin treated DCs, LPS stimulated DCs show
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dextran accumulated along the cell membrane and not throughout the cytoplasm
(Figure 15a). There was no significant difference between curcumin-treated and
untreated DCs in the LPS and poly I:C treated experimental groups (Table 5).
No stim

LPS

A
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Cur 20µM

B

DMSO
Cur 20µM
Cur 30µM

Change MFI

30000

20000

†

†

*

10000
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Figure 15. Curcumin reduces endocytosis in human dendritic cells. Confocal microscopy image
(a) and change in mean fluorescence intensity (MFI) as measured by flow cytometry (B).
Confocal images were captured using a 64x objective lens. Change in MFI was calculated by
subtracting the MFI at 4ºC from the MFI at 37ºC. * indicates significant curcumin effects p < 0.05;
† indicates significant stimulant effects p < 0.05.
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Table 5. Significance of curcumin effects on endocytosis: Comparison of DMSO vs. Cur 20µM
Mean
(DMSO)

Mean
(Cur 20µM)

Critical
p value

Observed
p value

Significance

23,729 ± 6196

13,596 ± 6353

0.017

0.0126

Yes

LPS

12,726 ± 12,237

9,850 ± 8,543

0.025

0.1165

No

Poly I:C

14,242 ± 9,198

12,964 ± 6,060

0.050

0.2960

No

No Stim

Table 6. Significance of the effects of stimulants on endocytosis: Comparison of DMSO (No Stim)
vs. Stimulant (Stim)
Mean
(No Stim)

Mean
(Stim)

Critical
p value

Observed
p value

Significance

LPS

23,729 ± 6196

12,726 ± 12,237

0.050

0.0418

Yes

Poly I:C

23,729 ± 6196

14,242 ± 9,198

0.050

0.0382

Yes

Curcumin Reduces Chemokine Secretion
Chemokines are cytokines that induce cellular migration. Two key
cytokines produced by DCs to attract inflammatory cells that are fractalkine
(CX3CL1) and IP-10 (CXCL10). The supernatant of DC experimental cultures
were analyzed for these chemokines by multiplex bead assay. Data are reported
as the average log10 transformed concentration of four donors. The significance
of the curcumin effects are shown in table 7. A lower concentration of curcumin
(20µM) was used in this experiment, since for previous experiments the changes
at this concentration were found to be significant. LPS was the only stimulant
used as curcumin effects do not seem to depend on the stimulant used.
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Curcumin reduces the levels of IP-10 and fractalkine produced in LPS-stimulated
DCs (Figure 16). The reduction in IP-10 production was found to be significant,
however, due to the low levels of fractalkine produced, the reduction was not
found to be significant (Table 7).
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Figure 16. Curcumin reduces chemokine production by dendritic cells. Error bars represent SEM
and * indicates p values < critical value.

Table 7. Significance of curcumin effects on chemokine production: Comparison DMSO vs. Cur
20µM
Mean
(DMSO)

Mean
(Cur 20µM)

Critical p

Observed p

Significant

IP-10

1.588 ± 0.769

1.144 ± 0.726

0.05

0.0828

No

Fractalkine

0.486 ± 0.015

0.382 ± 0.166

0.05

0.2113

No

IP-10

4.278 ± 0.036

3.008 ± 0.705

0.025

0.0009

Yes

Fractalkine

0.980 ± 0.456

0.486 ± 0.015

0.025

0.0970

No

No Stimulation

LPS
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Curcumin Prevents DC Chemotaxis
DC chemotaxis is a characteristic function of mature DCs. After they
acquire antigen they migrate towards lymphoid organs to stimulate T
lymphocytes. In order to assess the effects of curcumin on DC chemotaxis,
treated and stimulated cells were placed in a chemotaxis chamber and allowed to
migrate towards chemo-attractants CCL19 and CCL21. Data is reported as the
average percent cell migration of two donors. The significance of the effects of
curcumin are shown in table 8. The samples were normalized to the percentage
of cells migrating towards medium only. Curcumin treated cells are unable to
migrate towards the chemo-attractants CCL19 and CCL21 in response to LPS
(Figure 17). The chemokine receptor CCR7, expressed on the surface of DC
binds both the CCL21 and CCL19 ligands. The expression of CCR7 is not
affected by curcumin (Figure 18). CCR7 expression on DCs was evaluated by
surface marker immunofluorescence staining followed by flow cytometry (Figure
18a,b) and by western blot of whole cell lysate (Figure 18c).
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Figure 17. Curcumin prevents chemotaxis of dendritic cells in response to LPS. Cell migration
was normalized using percent cell migration towards culture medium. Error bars represent SEM
and * indicates p values < critical value. CCL21 – chemokine ligand 21 or exodus-2; CCL19 – chemokine ligand
19 or macrophage inflammatory protien-3-beta (MIP-3β)

Table 8. Significance of curcumin on dendritic cell chemotaxis: Comparison of DMSO vs. Cur
20µM
Mean
(DMSO)

Mean
(Cur 20µM)

Critical
p value

Observed
p value

Significance

CCL21
No Stim
LPS

0.599 ± 0.765
25.219 ± 1.457

0.160 ± 0.089
0.176 ± 0.083

0.050
0.025

0.2999
0.0123

No
Yes

CCL19
No Stim
LPS

0.780 ± 0.052
22.431 ± 3.225

0.117 ± 0.087
0.319 ± 0.439

0.025
0.050

0.0120
0.0371

Yes
Yes
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Figure 18. Expression of the chemokine receptor CCR7 is not affected by curcumin. CCR7
expression is determined both on the cell surface by immunofluorescence labeling and flow
cytometry (a and b) and intracellularly by western blot of whole cell lysate of a representative
donor (c). Histograms shown are from a single donor (a) and the bar chart shows the average
mean fluorescence intensity (MFI) of four donors with error bars representing SEM (b).
CCR7 – chemokine receptor 7; GAPDH – gylceraldehyde 3- phosphate dehydrogenase.
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Curcumin Reduces DC-induced T Cell Proliferation in an Allogeneic Mixed
Lymphocyte Reaction
The mixed lymphocyte reaction can be used as a measure of DC
maturation. Although iDCs can weakly stimulate T cell proliferation, mDCs initiate
a more robust proliferation of the T cell population in a co-culture. In order to
study the effects of curcumin in this process, iDCs were treated with curcumin,
stimulated with either LPS or poly I:C and then co-cultured with allogeneic CD4+
T helper cells from mismatched donors. The T cells were pre-loaded with CFSE,
an intracellular dye and proliferation was assessed after 5 days of co-culture by
flow cytometry. Flow cytometry data is represented as either the average mean
fluorescence intensity of six donors or of a representative donor. The significance
of curcumin effects and stimulant effects on the experimental populations are
shown in tables 8 and 9 respectively. For the flow cytometry analysis, gates were
set based on side scatter vs. forward scatter morphology (figure 19a) and those
cells were evaluated for CFSE expression. Proliferated cells have lower
fluorescence intensity of CFSE than unproliferated cells. Mature DCs induce
significantly higher proliferation by CD4+ T cells than iDCs (Figure 20). Though
iDCs induce some proliferation in the T helper cell population, curcumin
significantly impairs this ability as the number of proliferated cells is reduced from
25.28 (± 10.84) % to 4.83 (± 4.20) % on average. Even in the presence of the
stimulants LPS or poly I:C curcumin-treated DCS are unable to induce
proliferation of T helper cells at levels greater than 6.03 (± 3.50) % (Figure 19).
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Figure 19. Curcumin reduces DCs ability to induce proliferation in allogeneic CD4+ helper T cells
in a MLR. Data is representative of six donors. The gating strategy is shown in panel (a) and the
histograms of gated cell proliferation based on CFSE fluorescence is show in panel (b). CFSE –
carboxyfluorescein succinimdyl ester; MLR – mixed lymphocyte reaction.
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Figure 20. Curcumin-treated DCs show reduced CD4+ T cell proliferation in allogeneic MLR. Data
represents the average of six donors.

Table 9. Significance of curcumin effects on inducing proliferation of CD4+ T cells: Comparison of
DMSO vs. Cur 20µM
Mean
(DMSO)

Mean
(Cur 20µM)

Critical
p value

Observed
p value

Significance

No Stim

25.275 ± 10.838

4.825 ± 4.195

0.050

0.0215

Yes

LPS

38.750 ± 10.376

4.700 ± 1.337

0.017

0.0040

Yes

Poly I:C

36.900 ± 13.422

6.025 ± 3.491

0.025

0.0055

Yes

Table 10. Significance of stimulated DCS inducing T cell proliferation: Comparison DMSO (No
stim) vs. Stimulated cells (Stim)
Mean
(No Stim)

Mean
(Stim)

Critical
p value

Observed
p value

Significance

LPS

25.275 ± 10.838

38.750 ± 10.376

0.05

0.0045

Yes

Poly I:C

25.275 ± 10.838

36.900 ± 13.422

0.05

0.0570

No
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Curcumin Induces a CD4+ CD25+ T Regulatory Cell Population
Mature DCs will induce T helper cell differentiation. In order to assess the
effects of curcumin on the phenotype of proliferated T cells in co-culture, cells
were immunoflourescently labeled for FoxP3 and CD25. Proliferated T cells were
gated and only that population was analyzed for surface marker expression
(Figure 22a). Curcumin-treated DCs, both stimulated and unstimulated induce a
CD4+ CD25+ FoxP3+ population from the proliferated T cell population (Figures
21 and 22b). Culture supernatant was also assessed for T helper cytokines IL-2,
Il-4, IL-5, IL-10, IL-13 and IFNγ. Data is reported as average log10 concentration
of four donors. Curcumin-treated DCs induced significantly lower cytokine

% FoxP3+ CD25+ cells

production from the T cells in co-culture.
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Figure 21. Curcumin-treated DCs induce regulatory T cells in MLR. Data represents the average
percentage of FoxP3+ CD25+ T cells of four donors. Only the proliferated cell population was
analyzed. Error bars represent the SEM.
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Figure 22. Curcumin induces CD4+ CD25+ FoxP3+ regulatory T cells. After 5 days of co-culture
with curcumin-treated and stimulated DCs in an allogeneic MLR, T cells were immunofluorescently labeled and analyzed by flow cytometry. The gating strategy is outlined in panel (a);
cells are gated based on morphology and then proliferated T cells are gated and analyzed for
FoxP3 and CD25 expression. The numbers are the relative percentages of proliferated cells (b)
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Figure 23. Curcumin reduces T helper cytokine production after five days of co-culture in
allogeneic MLR with DCs. Cytokines were measured from the supernatant after T cell co-culture
with curcumin-treated, stimulated DCs. Data is reported as average log10 concentration ± SEM.
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Table 11. Significance of the effects of curcumin on DC-induced T cell cytokine production
Mean
(DMSO)

Mean
(Cur 20µM)

Critical p

Observed p

Significant

IL-2

1.270 ±0.201

0.477 ± 0.000

0.017

0.0021

Yes

IL-10

2.941 ± 0.226

0.925 ± 0.383

0.017

0.0013

Yes

IL-4

1.886 ± 0.217

1.425 ± 0.146

0.050

0.0320

Yes

IL-13

2.463 ± 0.433

0.843 ± 0.486

0.025

0.0075

Yes

IL-5

1.485 ± 0.286

0.477 ± 0.000

0.025

0.0029

Yes

IFNγ

2.213 ± 0.142

0944 ± 0.464

0.025

0.0027

Yes

IL-2

1.777 ± 0.350

0.477 ± 0.000

0.025

0.0025

Yes

IL-10

3.100 ± 0.279

1.213 ± 0.517

0.025

0.0034

Yes

IL-4

2.054 ± 0.251

1.452 ± 0.142

0.017

0.0061

Yes

IL-13

2.792 ± 0.407

0.826 ± 0.394

0.017

0.0013

Yes

IL-5

1.979 ± 0.319

0.477 ± 0.000

0.017

0.0013

Yes

IFNγ

2.722 ± 0.230

0.933 ±0.121

0.017

0.0001

Yes

IL-2

1.516 ± 0.715

0.477 ± 0.000

0.050

0.0311

Yes

IL-10

2.571 ± 1.003

1.403 ± 0.440

0.050

0.0154

Yes

IL-4

1.904 ± 0.343

1.458 ± 0.136

0.025

0.0219

Yes

IL-13

2.230 ± 1.185

0.815 ± 0.394

0.050

0.0390

Yes

IL-5

1.506 ± 0.705

0.477 ± 0.000

0.050

0.0308

Yes

IFNγ

2.086 ± 0.926

0.921 ± 0.268

0.050

0.0408

Yes

No Stimulation

LPS

Poly I:C
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Aim 3: Curcumin Modulates the Actin Cytoskeleton

Microarray Analysis of Total RNA Reveals the Effects of Curcumin on Gene
Expression in Dendritic Cells
Curcumin has anti-inflammatory, anti-oxidant and anti-viral properties. It is
reasonable to speculate that changes in gene expression as well as protein
expression are in part responsible for these properties. In order to assess the
effect of curcumin on human dendritic cells, DCs were cultured with curcumin
and then stimulated with LPS. Total RNA was analyzed using an Affymetrix HG
U133 plus 2 genome array. Ingenuity pathways analysis (IPA) software was used
to identify pathways that may be affected. Table 12 shows some pathways that
were most significantly affected by curcumin treatment as identified by IPA
software. Many of the pathways affected are associated with cell structure,
motility and function. These pathways also have many of the same molecules in
common. Upon closer inspection of the actin cytoskeleton pathway, though many
genes are unaffected, there are some genes that show an increase or decrease
in expression in response to curcumin-treated and stimulated cells when
compared to LPS-stimulated cells (Table 13). Of interest are those genes that
are down-regulated in curcumin-treated and stimulated cells such as nexilin
which decreased 129 fold. A few GTPases and Rho family members were downregulated along with WASP interacting protein, plexin and a tubulin-specific
chaperone.
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Table 12. Some pathways affected by curcumin as determined by Ingenuity pathways analysis
software.
Pathway

-Log(P-value)

Axonal Guidance Signaling

0.01540

Purine Metabolism

0.01220

Glucocorticoid Receptor Signaling

0.01060

Xenobiotic Metabolism Signaling

0.00966

Huntington's Disease Signaling

0.00904

Actin Cytoskeleton Signaling

0.00868

G-Protein Coupled Receptor Signaling

0.00828

Integrin Signaling

0.00810

Protein Ubiquitination Pathway

0.00801

Leukocyte Extravasation Signaling

0.00779

LPS/IL-1 Mediated Inhibition of RXR Function

0.00766

ERK/MAPK Signaling

0.00766

NRF2-mediated Oxidative Stress Response

0.00735

Calcium Signaling

0.00735

Ephrin Receptor Signaling

0.00726

Acute Phase Response Signaling

0.00717

RAR Activation

0.00703

Wnt/β2-catenin Signaling

0.00681

cAMP-mediated Signaling

0.00663

PPARα/RXRα Activation

0.00659
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Table 13. Actin cytoskeleton pathway genes affected by curcumin.
Fold change
Gene

Cur 20µM + LPS

Symbol

Gene description

vs LPS

RHOBTB1

Rho-related BTB domain containing 1

11.761

PLEC1

plectin 1, intermediate filament binding protein

5.332

SVIL

supervillin

4.815

FGD6

FYVE, RhoGEF and PH domain containing 6

4.408

MAP7

microtubule-associated protein 7

4.292

CDC42EP3

CDC42 effector protein 3

4.081

ARHGDIB

Rho GDP dissociation inhibitor (GDI) beta

3.836

RHOBTB2

Rho-related BTB domain containing 2

3.727

SPTAN1

spectrin, alpha, non-erythrocytic 1 (alpha-fodrin)

3.4278

SPTBN1

spectrin, beta, non-erythrocytic 1

2.3971

RASA4

RAS p21 protein activator 4

1.994

PAK1

p21/Cdc42/Rac1-activated kinase 1

1.172

VCL

vinculin

1.155

FGD4

FYVE, RhoGEF and PH domain containing 4

-1.074

CDC42SE1

Cdc42 small effector 1

-1.408

RND3

Rho family GTPase 3

-1.442

PHACTR2

phosphatase and actin regulator 2

-1.454

PHACTR4

phosphatase and actin regulator 4

-1.582

RAB12

RAB12, member RAS oncogene family

-1.659

MYOZ3

myozenin 3

-1.687

ARHGAP25

Rho GTPase activating protein 25

-1.835

RAB30

RAB30, member RAS oncogene family

-1.888

TBCD

tubulin-specific chaperone d

-2.161

WASPIP

Wiskott-Aldrich syndrome protein interacting protein -2.214

MASTL

microtubule associated serine/threonine kinase-like -2.885

PLXNA1

plexin A1

-3.426

ARHGAP25

Rho GTPase activating protein 25

-4.224

RHOH

ras homolog gene family, member H

-4.681

SCIN

scinderin

-4.695

RABGAP1L

RAB GTPase activating protein 1-like

-4.976

NEXN

nexilin (F-actin binding protein)

-129.149
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Curcumin Alters the Actin Cytoskeleton in Human DCs
The actin cytoskeleton of DCs is responsible for its shape and function.
We hypothesize that curcumin can alter the conformation of the cytoskeleton and
so provide a mechanism for its observed anti-inflammatory effects. Fluorescently
labeled phalloidin was used to visualize actin in this experiment. In order to
assess the effect of curcumin on the cell architecture, DCs were treated with
curcumin, washed, fixed with 4% paraformaldehyde and stained with Alexa 555phalloidin in suspension. The cell nucleus was visualized using mounting
medium containing the nuclear dye 4', 6-diamidino-2-phenylindole (DAPI).
Images were captured using a confocal microscope and representative z slices
are shown in figure 24. Cytochalasin B (CytoB) prevents actin polymer elongation
and causes cells to become more rounded. It was used as a control in this study.
Increasing concentrations of curcumin causes DCs to become more rounded and
less filamentous. The rounding and loss of protrusions is similar to what was
observed in the presence of the actin inhibitor CytoB (Figure 25).
The actin cytoskeleton plays an important role in cell adhesion and
motility. In order to assess curcumin effects, iDCs were allowed to adhere to
gelatin coated cover slips for 2 hrs at 37ºC (5%CO2 and 95% air). iDCs were
either treated with curcumin or stimulated. Actin accumulates at podosomes
towards the leading edge of the iDCs (Figure 24, left). Curcumin-treated cells
show podosome formation, but the cells are not elongated (Figure 24, center).
Maturing LPS-stimulated DCs do not show podosomes but rather stress fiber
formation (Figure 24, right). In order to assess the effect of curcumin on cell
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attachment, DCs are treated with curcumin and stimulated before they are
allowed to attach to poly L-lysine coated slides. Curcumin-treated DCs have a
rounded morphology and do not adhere tightly to the substrate (Figure 26,
center). iDCs and LPS-stimulated DCs adhere and are polarized with leadingedge lamellapodia (Figure 26, left). DCs treated with an actin inhibitor,
cytochalasin B, were rounded and loosely adherent (Figure 26, right). The Rho
GTPases play an essential role in cellular organization. Curcumin reduces the
activity of Rac1 and Cdc42 GTPases evidenced by western blotting of whole cell
lysate using phospho-antibodies. The expression of Cdc42 was not affected
(Figure 27).

DMSO

Cur 20µM

LPS

Figure 24. Curcumin interferes with DC motility and attachment. DCs were allowed to adhere to
gelatin for 2 hrs at 37ºC, 5% CO2 and 95% air. Curcumin and LPS were added to appropriate
wells. After 1hour, cells were fixed with 4% paraformaldehyde and stained with phalloidin to
visualize f-actin. Images were captured with a confocal microscope using a 63x objective lens.
Red – Alexa 555-phalloidin; blue – 4', 6-diamidino-2-phenylindole (DAPI); green – curcumin
fluorescing in FITC channel.
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iDC

Cur 10µM

Cur 50µM

DMSO

Cur 20µM

Cur 80µM

Cytochalasin B (20µM)

Cur 30µM

Cur 100µM

Figure 25. Curcumin changes DC morphology in a concentration dependent manor. DCS were
fixed, stained and imaged in suspension to maintain their three-dimensional shape. Curcumin
inhibits actin similar to cytochalasin B. The nucleus if the cell is represented by the blue color 4',
6-diamidino-2-phenylindole (DAPI), the actin is stained red (Alexa 555), curcumin fluoresces at
about 435nm and is detected in the FITC channel. This accounts for the increasing green color in
the cytoplasm of the cells as the concentration of curcumin increases. iDC – immature DC
(untreated); DMSO – dimethyl sulfoxide; Cytochalasin B – an actin inhibitor; Cur - curcumin
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Cur 20µM

CytoB

LPS

No Stim

DMSO

Figure 26. Curcumin affects DC adhesion. DCs were cultured with curcumin and stimulated with
LPS overnight, washed and allowed to adhere to poly L-lysine coated slides for 2 hrs. Cells were
fixed with 4% paraformaldehyde and stained for actin (Alexa 555-phalloidin). Images were

Cur 20µM + LPS

LPS

Cur 20µM

DMSO

captured with a confocal microscope using a 40x objective lens.

phospho-Rac1/cdc42
Cdc42

Figure 27. Curcumin reduces the activity of the Rac1/Cdc42 kinases. Western blots from whole
cell lysate of curcumin-treated stimulated DCs.
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Curcumin-Induced Reduction in Endocytosis May be Due to Actin Inhibition.
The actin cytoskeleton plays a key role in iDC endocytosis. In order to
assess whether the curcumin-induced reduction in phagocytosis is mediated by
actin inhibition, a known actin inhibitor, cytoB, was used as a control. CytoBtreated cells showed a similar reduction in phagocytosis to curcumin treated cells
(Figure 28).

Change MFI

75000

50000

25000

0

DMSO

Cur 20 µM

CB

LPS

Cur 20+LPS

Figure 28. Disruption of the actin cytoskeleton causes reduced endocytosis in immature DCs.
DCs cultured with curcumin for 24hrs and then endocytosis assay was performed.
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DISCUSSION

This is the first study to examine the effects of curcumin on human
dendritic cells in vitro. Donors for the study were selected at random and
supplied by Florida Blood Services, St. Petersburg, Florida. The concentrations
of curcumin used were based on those previously found efficacious in the
literature and confirmed not to be toxic to the cells by viability assays. All cultures
remained more than 90% viable up to 24hrs after curcumin addition. The
pharmacokinetics and pharmacodymanics of curcumin have been more
extensively studied in rodents than in humans (120). From the limited human
data available, the low bioavailability of curcumin limits its clinical usefulness
when administered orally. High doses can be administered without adverse
effects but the systemic distribution may not be sufficient to exert
pharmacological activity. Combining curcumin with other compounds, or using
drug delivery systems such as liposomes and nanoparticles provide an
alternative approach to overcome these issues (20, 122, 142). The
immunostimulants lipopolysacchaide (LPS) and polyinosinic:polycytidylic acid
(poly I:C) were used in this study to independently stimulate DC activation. LPS
via the toll-like receptor 4 (TLR4) pathway and poly I:C mimics viral infections
through TLR3. TNF-α signals through its receptor, TNF-R, which is a TLR71

independent pathway. These compounds were chosen to ensure the
immunostimulatory effects were not pathway specific or TLR dependent.
The inhibition of transcription factors NFκB and AP-1 and other cell
signaling pathways by curcumin explains some of the observations made in this
study, but curcumin may be targeting other essential cellular pathways as well.
The observations of this study suggest curcumin functions as an inhibitor of actin
signaling. Since f-actin reorganization is responsible for dendritic cell maturation
and function, its inhibition may be the mechanism by which curcumin prevents
DC response to stimulants. Elucidation of the underlying mechanism of curcumin
immunosuppression could lead to clinical applications of this novel antiinflammatory agent.
DCs aggregate in clusters in response to stimuli as a visual sign of
maturation (31). Cluster formation correlates with increased CD86, CD54 and
CD80 expression. Here we show curcumin impairs homotypic DC cluster
formation in response to LPS poly I:C and TNF-α in a concentration-dependent
manner. Adhesion molecules such as ICAM-1 (CD54) are important in cellular
interactions and in generating T cell response. Murine antigen presenting cells
(APCs) deficient in ICAM-1 have an impaired ability to induce T cell responses
(41, 126). CD11c, a member of the integrin family of proteins, is also important
for cell attachment and found in high levels on DCs. Curcumin significantly
reduces expression of both markers on the DC surface. The reduced CD11c
could be the result of curcumin-induced AP-1 inhibition (99).
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Mature or activated dendritic cells express elevated levels of costimulatory and antigen presenting molecules on their surface such as CD86,
CD83 and HLA-DR. If the antigen presenting machinery of DCs are impaired,
they can not effectively engage the T cells to initiate a response. HLA-DR
surface expression is only significantly inhibited at the 30µM concentration of
curcumin in LPS and TNF-α stimulated cells but in both concentrations
stimulated with poly I:C show a significant reduction in HLA-DR surface
expression. These data suggest curcumin may be interfering with the antigen
presenting machinery of DCs by affecting the expression of key presentation
molecules.
Mature monocyte-derived DCs secrete IL-12, IL-10 and other proinflammatory cytokines. Stimulated curcumin-treated DCs produce significantly
lower levels of IL-12, IL-10, IL-6 and TNF-α when compared to the controls
creating a Th2 permissive environment. Though the reduction of TNF-α was
significant, they were not reduced to the levels of the unstimulated controls.
These findings correlate with those from the study by Kim et al. (69) which shows
curcumin prevents immunostimulatory function of murine bone marrow-derived
cells. They along with others show curcumin is a potent inhibitor of NFκB and
AP-1 activation as well as MAPK signaling (59, 149). This provides a reasonable
explanation for the observed reduction of IL-12 and IL-10 levels in this study.
This is the first study to report that curcumin decreases IL-10 in human DCs.
TNF-α expression is controlled by other transcription factors such as
lipopolysaccharide-induced TNF factor (LITAF) (136) or interferon regulatory73

factor 3 (IRF3) (111) that may not be affected by curcumin, allowing the
transcription of some TNF-α independent of the NFκB pathway.
Capture and presentation of antigen is an important feature of DC biology.
This provides the link between innate and adaptive immunity. Immature DCs are
highly endocytic, a feature which is lost when cells become mature. We find
curcumin reduces endocytosis in non-stimulated DCs. There is a significant
decrease in dextran uptake by non-stimulated cells treated with curcumin similar
to stimulated cells, but not in stimulated cells. There are conflicting reports on the
effects of curcumin on antigen capture; a few studies show increased
endocytosis, while others show suppression (44). Our findings indicate curcumin
interferes with antigen handling in human DCs.
Mature DCs travel to the lymph nodes where they present processed
antigen to T cells. Migration towards chemo-attractants is a feature of mature
DCs (81). They also secrete chemokines to attract responder cells to the site of
injury or inflammation. Monocyte-derived DCs migrate in response to CCL19 or
macrophage-inflammatory protein-3beta (MIP-3β) and CCL21 or exodus-2, which
are expressed in the lymph nodes. Both chemokines bind to the CCR7 receptor
on the DC surface. Though CCR7 expression is not affected, curcumin prevents
migration towards CCL19 and CCL21 in a chemotaxis assay and also reduces
the levels of chemokines fractalkine (CX3CL1) and interferon producing factor
(IP-10). Both fractalkine and IP-10 attract inflammatory cells to sites of
inflammation. Fractalkine attracts T cells, monocytes and microglia and mediates
firm cell adhesion (17, 87). It also induces actin polymerization in human
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dendritic cells (34). IP-10 is produced in response to IFNγ and LPS. This
chemokine plays an important role in effector T cell trafficking (68). Poly I:C
stimulated cells did not migrate in response to the chemokines, even in the
absence of curcumin. By preventing DC migration, curcumin reduces the
probability of the DC encountering T cells to initiate a specific immune response.
Reduced chemokine secretion will stem the flow of inflammatory cell traffic to
sites of inflammation.
The mixed lymphocyte reaction (MLR) is used as the basic test of DC
function since it measures their ability to stimulate proliferation of an allogeneic T
cell population. Studies show curcumin can inhibit MLR (42, 57, 125, 153).
Immature DCs will weakly stimulate proliferation, while the mature DCs will
induce a significantly more robust response. This was observed in this study as
there was a significant increase in the amount of T cell proliferation in the
stimulated groups compared to the non-stimulated group. Increased expression
of co-stimulatory markers on the surface of DCs is essential for T cell interaction
and proliferation. Curcumin-treated DCs, both stimulated and non-stimulated,
show muted T cell proliferation (Figures 19 and 20). Curcumin inhibits the Th1
profile in antigen-primed CD4+ T cells while promoting the Th2 profile by
suppressing IL-12 production in macrophages (66, 67). We observe that
curcumin suppresses IL-12 production in DCs, but the cytokines produced after
the MLR were mixed Th1/Th2. There was no clear delineation in either direction
and the levels were very low. The low level of expression is most likely due to the
reduced number of proliferated T cells generated by the co-culture. The mixed
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phenotype could also be due to the ratio of DC to T cells used in the reaction
(135). Curcumin-treated DCs induce a low level of proliferation and those
proliferated cells express CD25 and Foxp3. This implies that curcumin is
conferring a tolerogenic property to DCs. A measure of this propensity is the
capacity to expand Foxp3 expressing lymphocytes (83, 139). It is suggested that
an environment containing IL-10 can induce tolerogenic DCs (63, 89, 90) but in
this study, the levels of IL-10 are only slightly (not significantly) elevated above
control levels in both DC culture and co-culture, suggesting there may be an
alternative mechanism at play.
We show that curcumin is able to exert profound effects on the expression
of genes involved with multiple signaling pathways associated with cytoskeleton
organization and function. These pathways include axonal guidance signaling,
glucocorticoid receptor signaling, actin cytoskeleton signaling.
Immunofluorescence staining reveals curcumin interferes with cell actin based
cell motility, attachment and microfilament organization on human dendritic cells
in vitro. The actin inhibitor cytochalasin B was used as a control in most
experiments to confirm the effects noted are most likely due to curcumin’s effects
on f-actin organization.
The regulation of the DC cytoskeleton is important in DC – T cell
interactions (18). Little is known about the effect of curcumin on cytoskeletal
rearrangement. One study reveals curcumin significantly alters the actin
cytoskeleton in prostate cancer cells (56). Based on this premise, curcumininduced alterations in DC cytoskeleton could account for our observations. DC
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migration involves regulation of the actin assembly. The cells must form
protrusions such as filapodia and lamellapodia, form adhesions and retract its tail
(80). Curcumin reduces expression of adhesion molecules and though
lamellapodia and podosome formation appears to be unaffected, the cells are
more rounded and we conclude less motile as there is the absence of the trailing
edge seen in the non curcumin-treated cells and these cells do not seem to
polarize in any particular direction. Cells were allowed to adhere to coated slides
before curcumin treatment and LPS stimulation.
For a more three-dimensional viewpoint, the cells that were imaged in
suspension show a dramatic change in morphology. As the concentration of
curcumin increases, the surface of the cell becomes more rounded and smooth
and less elongated projections are visible. This results in an overall decrease in
the cell surface area and so will affect the ability of the cell to interact with other
cells such as T cells. The changes observed are similar to those induced by
CytoB therefore we can infer that curcumin is inhibiting f-actin polymerization.
Curcumin-treated DC show reduced attachment. They did not polarize or adhere
strongly to the surface of the poly L-lysine coated slides as the non-treated cells
did. The morphology was similar to that of the CytoB treated cells which clearly
indicates the reduced attachment is due to inhibition of f-actin.
The Rho family of GTPases is central to the reorganization of the actin
cytoskeleton. Two key members are Rac1 and Cdc42. They participate in the
control of cell migration, endocytosis and antigen presentation (43, 124). As
determined by western blot analysis, curcumin reduces the activity of these
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GTPases and so modulates the function of DCs in part through inhibition of actin
signaling. The reduction in endocytosis observed in curcumin-treated cells may
be due in part to the inhibition of actin pathway signaling. This is evidenced in
figure 28 in which curcumin-treated cells show a similar level of endocytosis to
that of CytoB-treated cells.
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CONCLUSION
Curcumin reduces the DC response to immune stimulants by reducing cell
maturation and preventing normal cell function. It causes reduced expression of
the surface markers CD86, CD84, HLA-DR, CD40 as well as the adhesion
molecules CD11c and CD54 in response to a variety of external stimulants when
compared to the untreated controls. Stimulant-induced cytokine and chemokine
production was also reduced as a result of curcumin treatment. Functional
aspects of DC maturation were also affected by curcumin. The high endocytic
capacity of iDCs was significantly reduced in curcumin culture. Chemotaxis and
DC-induced T cell proliferation was also abrogated. The few T cells that
proliferated in co-culture expressed CD25 and Foxp3 indicating a regulatory
population and curcumin may induce a tolerogenic DC. Curcumin affects cell
architecture by inhibiting f-actin.

79

LIMITATIONS OF THE STUDY
The major limitation of this study was the use of donors from Florida blood
services. Without access to medical records or individual medical history, we are
left to assume the participants were in good health. There is also the aspect of
human subject variability. We elected to use a repeated measures analysis
approach for data analysis in an effort to control for this variability. There is no
established standard for the response of a donor to curcumin. The data was log
transformed to ensure a normal distribution for statistical analysis. The age,
gender and ethnicity of the donors may have played a role in the noted variation
in responses. A larger sample size would be needed to address these aspects of
the study.
The concentrations of curcumin used in the study, though non-toxic, are
not physiological. Due to the pharmacokinetic properties of curcumin and low
bioavailability, the experimental concentrations can not be achieved through daily
ingestion. In order to achieve these levels in the circulation, a special formulation
may need to be engineered to prevent biodegradation. The method of delivery
needs to be taken into account as well. When administered systemically
curcumin will affect multiple cell types. To reproduce the DC-specific effects
observed here, a formulation needs to be developed that will target curcumin
specifically to DCs.
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FUTURE DIRECTIONS
Further investigation into the generation of tolerogenic DCs by curcumin
would be important in elucidating the immunosuppressive role of curcumin. This
would include further characterization of the regulatory T cell population
generated in co-culture. The DC to T cell ratio can be adjusted to examine the
effects on the phenotype of these cells. This phenomenon needs to be examined
in vivo using a mouse model of allergic asthma. If curcumin-DCs induce a
regulatory T cell population, then the Th2 type response should be reduced.
Using curcumin to target DCs and induce immune tolerance would make it an
effective treatment for inflammation.
Further investigation into the effects of curcumin on the actin cytoskeleton
needs to be carried out as well. It would be important to determine if curcumin
binds to any members of the actin cytoskeleton pathway. Disruption of f-actin
organization affects cell attachment and function. Elucidation of the underlying
mechanism is important for the development on novel curcumin based
therapeutics.
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Appendix A: List of Definitions

Adaptive immunity: host defenses that are mediated by T and B cells after
exposure to antigen that generate a specific or memory response or self/non-self
recognition.
Allergen: non-infectious antigen that induces a hypersensitivity or allergic
reaction.
Allogeneic: individuals of the same species that differ genetically.
Antigen: any molecule that can bind to an antibody. Some have the ability to
stimulate antibody production.
Chemokine: small proteins that induce that mediate chemotaxis by regulating
the expression of leukocyte integrins.
Chemo-attractant: a substance that attracts leucocytes
Chemotaxis: directional movement of cells.
CD4: cluster of differentiation 4 is present on thymocytes, monocytes,
macrophages and is a co-receptor of MHC Class II
CD11c: cluster of differentiation 11c is present on myeloid cells and binds
fibrinogen. It can be used to identify dendritic cells.
CD80: cluster of differentiation 80 is present on dendritic cells and is a ligand for
CD28 on T cells. It is important in the activation of naïve T cells through costimulation (signal 2).
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CD83: cluster of differentiation 83 is present on dendritic, B and Langerhans’
cells. It is a marker for activated dendritic cells and may assist in antigen
presentation or cellular interactions that follow lymphocyte activation
CD86: cluster of differentiation 86 is present on dendritic, monocytes and
activated B cells and it is a ligand for CD28 on T cells. It is important in the
activation of naïve T through co-stimulation (signal 2).
CD54: cluster of differentiation 54 is present on hematopoietic and nonhematopoietic cells. Also known as intercellular adhesion molecule (ICAM-1) and
is involved in adhesion of neutrophils and is a receptor for rhinovirus.
Cluster of differentiation (CD): a monocolonal antibody that identifies surface
molecules, used to identify various immune cells.
Cytokine: low molecular weight proteins that regulate the intensity and duration
of the immune response by affecting the functions on other immune cells as well
as the cell that produces it.
Dendritic cell (DC): professional antigen presenting cell and the most potent
activator of T and B cells. They are link the innate and adaptive immune systems
and reside in tissues exposed to the external environment such as the skin, lungs
and intestines.
Dimethyl sulfoxide (DMSO): a chemical compound that is a polar aprotic
solvent. It is an excellent solvent and cryoprotectant.
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Flow cytometry: a technique used to count, examine and sort microscopic
particles or cells suspended in a fluid stream. It uses the principles of light
scattering, light excitation, and emission of fluorochrome molecules to generate
specific multi-parameter data.
Homotypic cluster formation: clustering of dendritic cells with each other that is
an indicator of increased expression of adhesion molecules, chemokines and
chemokine receptors.
Human leukocyte antigen DR (HLA-DR): human leukocyte antigen -DR, the
term for MHC in humans is required for antigen presentation to T cells.
Innate immunity: non-specific host defense to invading pathogens such as
bacteria, virus and allergens that includes various recognition systems such as
toll-like receptors, endocytic, phagocytic and inflammatory mechanisms. The
innate immune response does not increase with repeated exposure.
Interferon gamma (IFNγ): cytokine that can induce cells to resist viral
replication. It is produced by CD4+ Th1 cells and is a type II interferon and has
antiviral, immunoregulatory, and anti-tumor properties.
Interferon-inducing protein 10 (IP-10): chemokine that selectively attracts Th1
lymphocytes and monocytes, and inhibits cytokine-stimulated hematopoietic
progenitor cell proliferation. Also called CXCL10.
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Interleukin 2 (IL-2): a T cell derived cytokine that stimulates growth and
differentiation of T cells, B cells, NK cells, monocytes, macrophages. A central
cytokine in the development of an adaptive immune response.
Interleukin 4 (IL-4): a cytokine that is secreted by Th2 cells. It enhances both
secretion and cell surface expression of IgE and IgG1. An important cytokine in
allergic disease and has overlapping functions with IL-13.
Interleukin 5 (IL-5): secreted by Th2 and mast cells that is a key mediator in
eosinophil activation. An important cytokine in allergic disease.
Interleukin 6 (IL-6): both a pro-inflammatory and anti-inflammatory cytokine.
Important mediator of fever and of the acute phase response and secreted in
response to activation of the innate immune system. High IL-6 It is associated
with both Th1 and Th2 responses and low IL6 is associated with Treg responses.
Interleukin 8 (IL-8): inflammatory chemokine produced by many cell types.
Mainly functions as a neutrophil chemoattractant.
Interleukin 10 (IL-10): secreted by Th0 cells blocks cytokine synthesis by Th1
cells.
Interleukin 12 p70 (IL-12p70): Th1 polarizing type cytokine secreted mainly by
dendritic cells. Induces IFNγ production and proliferation/differentiation of Th1
cells.
Interleukin 13 (IL-13): secreted by Th2 cells, involved in the up-regulation of IgE
secretion by B cells. An important cytokine in allergic disease.
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Ligand: general term for a molecule recognized by a receptor.
MHC Class II: major histocompatibility complex class II present on antigen
presenting cells with the primary function to present peptide antigens, both self
and non-self, to lymphocytes (T cells) for the purpose of eliciting an immune
response.
Mixed lymphocyte reaction (MLR): lymphocytes from two individuals are
cultured together for several days in order to induce T cell proliferation.
Monocyte: mononuclear phagocytic leukocyte
Monocyte-derived dendritic cells (mdDCs): dendritic cells obtained by
culturing CD14+ monocytes with granulocyte-macrophage colony-stimulating
factor (GM-CSF) and interleukin 4 (IL4).
Phagocytosis: the engulfment of particles, bacteria, cell debris, etc. by cells. A
characteristic function of macrophages and dendritic cells.
Polyinosinic-polycytidylic acid (Poly I:C): a commercially available synthetic
double stranded RNA. A toll-like receptor 3 ligand that mimics viral infection and
induces a Th1 response.
T cells (TC): thymic lymphocytes that developed in the thymus.
T cell proliferation: The reproduction of a T cell to produce two daughter cells.
Naïve T helper lymphocyte (Th0): T lymphocytes that have never engaged a
specific antigen.
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T helper type 1 lymphocyte (Th1): T lymphocyte characterized by the cytokines
they produce (especially IFNγ). An increase in Th1 cytokines are associated with
autoimmune diseases.
T helper type 2 lymphocyte (Th2): T lymphocyte characterized by the cytokines
they produce (especially IL4, IL5, IL13). An increase in Th2 cytokines are
associated with allergic diseases.
Toll-like receptor (TLR): recognize pathogen-associated molecular patterns
(PAMPs) that are expressed on infectious agents. They mediate the production
of cytokines necessary for the development of effective immunity.
Toll-like receptor 3 (TLR3): one of the toll-like receptors that recognizes double
stranded RNA of viruses.
Toll-like receptor 4 (TLR4): one of the toll-like receptors that recognize bacterial
lpipoplysachharide on Gram-negative bacteria.
T regulatory lymphocyte (Treg): T lymphocyte characterized by the cytokines
they produce (IL10, TGF-β). They have the ability to inhibit T cell responses and
induce tolerance.
Tumor necrosis factor alpha (TNF-α): a pleiotropic inflammatory cytokine
involved in apoptotic cell death/proliferation, differentiation, inflammation, tumor
growth, and viral replication.
Viability: ability of the cell to survive.
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ABSTRACT
Curcumin, a compound found in the Indian spice turmeric, has antiinflammatory and immunomodulatory properties, though the mechanism remains
unclear. Dendritic cells (DCs) are important to generating an immune response
and the effect of curcumin on human DCs has not been explored. The role
curcumin in the DC response to bacterial and viral infection was investigated in
vitro using LPS and Poly I:C as models of infection. CD14+ monocytes, isolated
from human peripheral blood, were cultured in GM-CSF- and IL-4-supplemented
medium to generate immature DCs. Cultures were incubated with curcumin,
stimulated with LPS or Poly I:C and functional assays were performed. Curcumin
prevents DCs from responding to immunostimulants and inducing CD4+ T cell
proliferation by blocking maturation marker, cytokine and chemokine expression
and reducing both migration and endocytosis. These data suggest a therapeutic
role for curcumin as an immune suppressant.
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INTRODUCTION
Curcumin is a biologically active compound found in the Indian spice
turmeric. It belongs to a family of compounds called curcuminoids and usually
comprises about 3% of turmeric powder. The spice is commonly used as a
preservative for foods and a yellow dye or coloring for textiles and as an
ingredient in pharmaceuticals and cosmetics. For many centuries curcumin has
been used as an antiseptic, analgesic, appetite suppressant, anti-inflammatory
agent, anti-oxidant, anti-malarial, and insect repellant [1,2]. The pharmacological
potential of curcumin is under investigation. Researchers found that it has antiinflammatory, anti-oxidant, anti-parasitic, anti-viral, and anti-cancer properties [3–
6]. It targets transcription factors, cytokines, cell adhesion molecules, surface
receptors, growth factors, and kinases, among other molecules [7–10], and
directly binds to a variety of surface and intracellular proteins causing direct
cellular pathway inhibition or activation of secondary cellular responses [2,11].
Dendritic cells are the sentinels of the immune system and regulate the
immune response. Immature or resting dendritic cells reside in peripheral organs
where they monitor the surrounding tissue for invading microorganisms. They
alert the immune system to the presence of pathogens by engulfing them,
processing the foreign proteins and presenting the peptide fragments on their
surface. After DCs are activated, they mature and migrate to the lymphoid tissue
where they prime T lymphocytes and stimulate a specific or adaptive response
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[12,13]. Maturation of dendritic cells involves changes in gene expression and
activation of signaling pathways, and it is reasonable to hypothesize that
curcumin can modulate some of these pathways and thereby prevent DC
maturation and alter function. While a study by Kim et al. reveals that curcumin
impairs the immunostimulatory function of murine dendritic cells [14], its effects
on human dendritic cells remain unknown. Curcumin’s effects on human DC
stimulation are examined in this study. Modulating the DC response could
provide an effective approach to treat and control unwanted inflammation.
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MATERIALS AND METHODS
Reagents. Curcumin (from Curcuma longa) was obtained from Sigma
Aldrich (St. Louis, MO) and dissolved in DMSO. Buffy coats were obtained from
Florida Blood Services (St. Petersburg, Florida). Six donors, four males and two
females, in good health and ranging in age from 18 to 50 were used for the
study. Cell isolation reagents CD14 microbeads and CD4+ T cell isolation kit
were obtained from Miltenyi Biotec (Auburn, CA). Histopaque_-1077 and was
obtained from Sigma Aldrich and recombinant human cytokines GM-CSF and IL4 were obtained from PeproTech (Rocky Hill, NJ). All other cell culture reagents
were obtained from GIBCO Invitrogen (Carlsbad, CA). LPS, poly I:C and PHA
were obtained from Sigma Aldrich (St. Louis, MO). CFSE and Alexa-647
conjugated dextran (molecular weight 10,000) were obtained from Molecular
Probes Invitrogen (Carlsbad, CA). LINCOplex Multiplex cytokine assay kits were
purchased from Millipore (Temecula, CA). All CD11c, HLA-DR, CD86, CD83, and
CD54 antibodies were obtained from BD Biosciences (San Jose, CA). CCL19
and CCL21 were obtained from PeproTech (Rocky Hill, NJ).
Cell Isolation and Culture. CD14+ monocytes were isolated and cultured
as described by Picki et al. [15]. Briefly, leukocytes were extracted from buffy
coats using Histopaque-1077. Monocytes expressing CD14 were positively
selected with magnetic microbeads. Purity (>90%) was verified by staining with
anti-CD14 antibodies and analyzing by flow cytometry. Cells were cultured at 1 ×
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106 cells/ml in complete RPMI (10% FBS, 1% pen/strep, 10 mM Hepes, nonessential amino acids and 5 mM sodium pyruvate) with 20 ng/ml each rh IL-4 and
GM-CSF for 5–6 days, (supplementing at day three with fresh medium). Nonadherent and loosely adherent cells were removed on day five for analysis or
stimulation. On day 5, more than 90% of the harvested cells expressed CD11c
and HLA-DR. CD4+ T cells were isolated from the CD14+ fraction remaining
after monocyte depletion and cultured in complete RPMI. Purity was confirmed
by flow cytometry after CD4 staining.
Cell Treatment and Stimulation. Curcumin was added to cell culture (1 ×
106 cells/ml and 3 ml/well in 6-well plates) at concentrations of 20 or 30 µM.
DSMO was used as a control. After a 1 h incubation, LPS (1 µg/ml) or Poly I:C
(25 µg/ml) was added to the appropriate wells. Control wells received neither.
Cultures were incubated overnight at 37 ºC and 5% CO2/95% air. Cell viability
was 95% ± 0.06 after 24 h of culture under all conditions listed above as
determined by a viability assay using 7AAD incorporation.
Flow Cytometry. Cells were collected, washed and stained with
fluorochrome-conjugated antibodies specific for DC surface markers. Cells were
analyzed using the Becton Dickenson (BD) Canto II with HTS sampler and BD
FACSDivaTM software.
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Cytokine Assay. Culture supernatant was collected and cytokine levels
measured using the LINCOplex multiplex assay. Assays were performed in
duplicate according to the manufacturer’s instructions.
Chemotaxsis Assay. Treated and stimulated cells were collected, counted
and re-suspended at a concentration of 1 × 106 cells/ml. Fifty microliters of cell
suspension was placed in the upper chambers of 5 µm pore size polycarbonate
filter inserts in a 96-well microchemotaxis plate (Chemicon). The lower chambers
contained 40 µl of either CCL19 or CCL21 in 150 µl of medium. Control wells had
medium only. Input wells (in triplicate) contained 1 × 104 cells in the lower
chambers without chemokines. Cells were incubated at 37 ºC and 5% CO2/95%
air overnight. Migration was stopped by the removal of the inserts. Polystyrene
beads (1 × 104) were added to each well (lower chamber) and analyzed by flow
cytometry. The number of cells in each sample and input was calculated using
the following equation: Number of cells/well = (number of cell events × number of
bead events) × 104. Input cells = average [number of input cells/well × 5 (dilution
factor)]. The percentage migration for each sample (% input) is determined by
the following equation: Percent migration = (migrating cells × input cells) × 100.
Mixed Lymphocyte Reaction. CFSE labeling of CD4+ T cells was carried
out by resuspending cells in 1ml PBS containing 5% (v/v) FBS. 1.1 µl of the
CFSE stock (5 µM) was diluted in 110 µl of PBS and quickly mixed with the cell
suspension. After a 5 min incubation at room temperature, the reaction was
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stopped by adding ten volumes of room temperature PBS containing 5% (v/v)
FBS and centrifuging at 300g for 5 min at 20 ºC. Cells were washed twice and
resuspended in complete medium (1 × 106 cells/ml). The dendritic cell-T cell coculture was set up at a ratio of 1:16. Curcumin treated and stimulated DCs were
removed from culture and placed in 96-well plates in triplicate (6.25 × 103 cells in
100 µl per well). T cells (100 µl) were added to each well and cultures incubated
at 37 ºC and 5% CO2 /95% air for 5 days. CFSE fluorescence intensity was
measured by flow cytometry using the BD Canto II with HTS attachment and BD
FACS Diva software.
Endocytosis Assay. Cells were collected, washed and incubated with 1
mg/ml (per 1 × 106 cells) Alexa-647 conjugated dextran at either 4 ºC or 37 ºC for
1 h. Cells were washed with cold PBS and either analyzed by flow cytometry or
plated on gelatin coated cover slips and imaged by confocal microscopy. The
change in mean fluorescence intensity (MFI) is calculated as the difference
between the MFI of 37 ºC and 4 ºC cultures.
Microscopy. All bright field images were captured using the 4× objective of
an Olympus IX71 inverted fluorescent microscope with an attached DP70
camera. Fluorescent images were captured using the 63x objective of a Leica
scanning confocal microscope.
Statistical Analysis. Data was log transformed to ensure normal
distribution. Significance was determined using paired t tests (repeated
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measures) for planned comparisons with modified Bonferroni correction. Data
are presented as the average of six donors. Error bars represent SEM with p
values less than 0.05 considered statistically significant.
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RESULTS AND DISCUSSION
This is the first study to examine the effects of curcumin on human
dendritic cells in vitro. Donors for the study were selected at random and
supplied by Florida Blood Services, St. Petersburg, Florida. The concentrations
of curcumin used were based on those previously found efficacious in the
literature and confirmed not to be toxic to the cells by viability assays (data not
shown). All cultures remained more than 90% viable up to 24 h after curcumin
addition. The pharmacokinetics and pharmacodymanics of curcumin have been
more extensively studied in rodents than in humans [16]. From the limited human
data available, the low bioavailability of curcumin limits its clinical usefulness
when administered orally. High doses can be administered without adverse
effects but the systemic distribution may not be sufficient to exert
pharmacological activity. Combining curcumin with other compounds, or using
drug delivery systems such as liposomes and nanoparticles provide an
alternative approach to overcome these issues [17–19]. The immunostimulants
lipopolysacchaide (LPS) and polyinosinic:polycytidylic acid (poly I:C) were used
in this study to independently stimulate DC activation. LPS via the toll like
receptor 4 (TLR4) pathway and poly I:C mimics viral infections through TLR3.
These compounds were chosen to ensure the immunostimulatory effects were
not TLR dependent. Observed stimulant effects were found to be significant with
p values <0.05 by paired t test compared to non-stimulated controls.
120

Appendix C (Continued)

Curcumin Prevents Increased Maturation Marker Expression and Cytokine
Secretion
Mature dendritic cells express elevated levels of co-stimulatory and
antigen presenting molecules such as CD86, CD83 and HLA-DR on their
surface. If the antigen presenting machinery of DCs are impaired, they can not
effectively engage the T cells to initiate a response. Stimulated curcumin-treated
DCs do not significantly increase their surface expression of CD86 and CD83
above the control (Fig. 1A). HLA-DR surface expression is not significantly
inhibited by 20 µM curcumin. We can surmise that curcumin affects the antigen
presenting machinery by reducing co-stimulatory molecule expression but not the
antigen presenting molecules. Mature monocyte-derived DCs secrete IL-12, IL10, and other inflammatory cytokines. Stimulated curcumin-treated DCs produce
significantly lower levels of IL-12, IL-10, and TNFα when compared to the
controls (Fig. 1B) creating a Th2 permissive environment. IL-6 was also
significantly reduced by curcumin (data not shown). Though the reduction of
TNFα was significant, they were not reduced to the levels of the controls. These
findings correlate with those from the study by Kim et al. [14] which shows
curcumin prevents immuno-stimulatory function of murine bone marrow-derived
cells. They along with others show curcumin is a potent inhibitor of NF-κB and
AP-1 activation as well as MAPK signaling [20,21]. This provides a reasonable
explanation for the observed reduction of IL-12 and IL-10 levels in this study.
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TNFα expression is controlled by other transcription factors such as
lipopolysaccharide- induced TNF factor (LITAF) [22] or interferon regulatoryfactor 3 (IRF3) [23] that may not be affected by curcumin, allowing the
transcription of some TNFα independent of the NF-κB pathway.

Curcumin Prevents DC-Induced CD4+ T Cell Proliferation in the Mixed
Lymphocyte Reaction
The mixed lymphocyte reaction (MLR) is used as the basic test of DC
function since it measures their ability to stimulate proliferation of an allogeneic T
cell population. Studies show curcumin can inhibit MLR [24–27]. Immature DCs
will weakly stimulate proliferation, while the mature DCs will induce a significantly
more robust response (Fig. 2A). Increased expression of co-stimulatory markers
is essential for T cell interaction and proliferation. Curcumin-treated DCs, both
stimulated and non-stimulated, show muted T cell proliferation (Fig. 2A). These
observations and those in Fig. 1A imply there are factors at play other than the
expression levels of co-stimulatory and antigen presenting molecules. The
regulation of the DC cytoskeleton is important in DC–T Cell interactions [28].
Little is known about the effect of curcumin on cytoskeletal rearrangement. One
study reveals curcumin significantly alters the actin cytoskeleton in prostate
cancer cells [29]. Based on this premise, curcumin-induced alterations in DC
cytoskeleton could account for the observations in Fig. 2A. Analysis of the CD4 T
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Cell cytokines produced in the MLR revealed a Th2–biased response evidenced
by the increase in the IL-4:IFNγ ratio between untreated and curcumin treated
cells (Fig. 2B).

Curcumin Reduces Endocytosis
Capture and presentation of antigen is an important feature of DC biology.
This provides the link between innate and adaptive immunity. Immature DCs are
highly endocytic, a feature which is lost when cells become mature. We find
curcumin reduces endocytosis in non-stimulated DCs (Fig. 2C and D). There is a
significant decrease in dextran uptake by non-stimulated cells treated with
curcumin similar to stimulated cells, but not in stimulated cells. There are
conflicting reports on the effects of curcumin on antigen capture; a few studies
show increased endocytosis, while others show suppression [30]. Our findings
indicate curcumin interferes with antigen handling in human DCs.

Curcumin Prevents Homotypic Clustering and Surface Adhesion Marker
Expression
DCs aggregate in clusters in response to stimuli as a visual sign of
maturation [31]. Cluster formation correlates with increased CD86, CD54, and
CD80 expression. Here we show curcumin impairs homotypic DC cluster
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formation in response to both LPS and poly I:C in a concentration-dependent
manner (Fig. 3A). Adhesion molecules such as ICAM-1 (CD54) are important in
cellular interactions and in generating T cell response. Murine antigen presenting
cells (APCs) deficient in ICAM-1 have impaired ability to induce T cell responses
[32,33]. CD11c, a member of the integrin family of proteins, is also important for
cell attachment and found in high levels on DCs. Curcumin significantly reduces
expression of both markers on the DC surface (Fig. 3B and C). The reduced
CD11c could be the result of curcumin-induced AP-1 inhibition [34].

Curcumin Prevents DC Migration and Chemokine Secretion
Mature DCs travel to the lymph nodes where they present processed antigen to
T cells. Migration towards chemoattractants is a feature of mature DCs [35]. They
also secrete chemokines to attract responder cells to the site of injury or
inflammation. Monocyte-derived DCs migrate in response to CCL19 or
macrophage-inflammatory protein-3beta (MIP-3b) and CCL21 or exodus-2, which
are expressed in the lymph nodes. Both chemokines bind to the CCR7 receptor
on the DC surface. CCR7 expression is not affected by curcumin (data not
shown). Curcumin prevents migration towards CCL19 and CCL21 in a
chemotaxis assay (Fig. 4A) and also reduces the levels of chemokines
fractalkine (CX3CL1) and interferon producing factor (IP-10) (Fig. 4B and C).
Both fractalkine and IP-10 attract inflammatory cells to sites of inflammation. Poly
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I:C stimulated cells did not migrate in response to the chemokines, even in the
absence of curcumin (data not shown). By preventing DC migration, curcumin
reduces the probability of the DC encountering T cells to initiate a specific
immune response. Reduced chemokine secretion will stem the flow of
inflammatory cell traffic to sites of inflammation.
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CONCLUSIONS AND PERSPECTIVES
Curcumin acts in several ways as an immune suppressor of human
peripheral CD14+ monocyte-derrived DCs. It renders them non-responsive to the
immuno-stimulants LPS and poly I:C by reducing expression of co-stimulatory
and antigen presentation molecules expression and dampening the Th1-type
response while promoting a Th2 permissive environment. It also reduces
migration and adhesion molecule expression and reduces DC-induced
proliferation of allogeneic CD4+ T cells. The inhibition of transcription factors NFκB and AP-1 and other cell signaling pathways by curcumin provide a plausible
explanation for most of observations; however curcumin may be targeting other
essential cellular pathways as well. Based on our observations and reports from
other studies, we speculate curcumin may be disrupting the antigen handling and
presenting machinery of DCs in addition to transcription factor and signaling
pathway inhibition [30]. Elucidation of the mechanism of action of curcumin
immunosuppression could lead to clinical applications of this novel antiinflammatory agent.
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FIGURE LEGENDS

Fig. 1. Curcumin reduces maturation marker expression (A) and cytokine
Production (B) in human monocyte-derived dendritic cells. Surface marker
expression is measured as mean fluorescence intensity (MFI) by flow cytometry.
Cytokine levels were measured from culture supernatant using a multiplex assay
kit and expressed as log concentration. *Significance by one-tailed t-test of
planned comparisons p < 0.05.

Fig. 2. Curcumin reduces DC-induced proliferation of allogenieic CD4+ T cells (A)
and promotes a Th2-permissive environment with an increased IL4:IFNγ ratio (B)
in mixed lymphocyte reaction. Curcumin also reduces the endocytic capability of
DCs. Endocytosis of fluorescently labeled dextran was measured by change in
mean fluorescence intensity (MFI) between cells incubated at 37 ºC and 4 ºC (C)
and imaged by confocal microscopy of a representative donor (D). *Significance
by one-tailed t-test of planned comparisons p < 0.05.

Fig. 3. Curcumin prevents homotypic clustering of DCs in response to stimuli (A)
and reduces surface adhesion molecules CD54 (B) and CD11c (C). Surface
marker expression is measured as mean fluorescence intensity (MFI) by flow
cytometry. *Significance by one-tailed t-test of planned comparisons p < 0.05.
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Fig. 4. Curcumin prevents DC migration towards CCL19 and CCL21 (A) and
chemokine secretion in culture (B, C). Chemotaxis assay performed in 96-well
microchemotaxis plate with 5 lm pore size polycarbonate filters. Chemokine
levels were measured from culture supernatant using a multiplex assay kit.
*Significance by one-tailed t-test of planned comparisons p < 0.05.
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